Glutamina, barreira intestinal e disbiose em cães e gatos: da evidência humana à prática clínica veterinária integrativa
Glutamine, intestinal barrier and dysbiosis in dogs and cats: from human evidence to integrative veterinary clinical practice
Claudio Amichetti Junior — CRMV SP 75404VT Pós em Nutrição Animal · Pós em Farmacologia · Pós em Cannabis Medicinal
RESUMO
A glutamina é o aminoácido livre mais abundante no organismo e o principal substrato energético dos enterócitos, desempenhando papel central na manutenção da integridade da barreira intestinal. O interesse por sua suplementação cresceu a partir da divulgação em saúde humana, frequentemente apresentada de forma simplificada e sem distinção de espécie. Esta revisão narrativa tem como objetivo analisar criticamente a evidência disponível sobre glutamina, barreira intestinal e disbiose em cães e gatos, incluindo o contexto de imunossupressão viral felina. Foram consultadas bases indexadas, priorizando ensaios clínicos, revisões sistemáticas e estudos mecanísticos. Em cães, um ensaio clínico randomizado em parvovirose canina demonstrou redução significativa da duração da diarreia com glutamina oral na dose de 500 mg/kg/dia, embora com limitações metodológicas relevantes. Em gatos, não foram identificados ensaios clínicos de suplementação em enteropatia crônica ou disbiose, e a evidência disponível é indireta, derivada de análises metabolômicas. Em pacientes infectados pelo vírus da leucemia felina, o risco elevado de neoplasia impõe cautela adicional, uma vez que células tumorais podem apresentar dependência de glutamina. Conclui-se que a glutamina deve ser posicionada como coadjuvante sobre uma base dietética adequada e manejo da microbiota, nunca como substituto de terapia específica, sendo necessários ensaios clínicos veterinários bem desenhados.
Palavras-chave: glutamina; barreira intestinal; disbiose; enteropatia crônica; nutrição veterinária.
ABSTRACT
Glutamine is the most abundant free amino acid in the body and the main energy substrate for enterocytes, playing a central role in maintaining intestinal barrier integrity. Interest in its supplementation has grown from human health communication, often presented in simplified form and without species distinction. This narrative review aims to critically analyze the available evidence on glutamine, intestinal barrier and dysbiosis in dogs and cats, including the context of feline viral immunosuppression. Indexed databases were consulted, prioritizing clinical trials, systematic reviews and mechanistic studies. In dogs, a randomized clinical trial in canine parvovirus demonstrated a significant reduction in diarrhea duration with oral glutamine at 500 mg/kg/day, albeit with relevant methodological limitations. In cats, no clinical trials of supplementation in chronic enteropathy or dysbiosis were identified, and the available evidence is indirect, derived from metabolomic analyses. In feline leukemia virus-infected patients, the elevated risk of neoplasia imposes additional caution, since tumor cells may present glutamine dependency. It is concluded that glutamine should be positioned as an adjuvant on an adequate dietary basis and microbiota management, never as a substitute for specific therapy, and that well-designed veterinary clinical trials are needed.
Keywords: glutamine; intestinal barrier; dysbiosis; chronic enteropathy; veterinary nutrition.
1 INTRODUÇÃO
A glutamina é o aminoácido livre mais abundante no plasma e desempenha funções que ultrapassam sua classificação tradicional como aminoácido não essencial. Em condições fisiológicas de estresse catabólico, sua disponibilidade pode tornar-se limitante, o que justifica a designação de aminoácido condicionalmente essencial. O trato gastrointestinal consome parcela substancial da glutamina circulante, utilizando-a como fonte energética preferencial para os enterócitos e como precursor de nucleotídeos, glutationa e outros metabólitos essenciais à renovação epitelial.
Nas últimas décadas, esse conhecimento consolidou-se na literatura de nutrição clínica humana e passou a circular amplamente em conteúdos de divulgação, inclusive em redes sociais, onde a glutamina é frequentemente apresentada como recurso genérico para "melhorar a saúde intestinal e aumentar a imunidade". Essa comunicação simplificada, embora didática, tende a suprimir elementos decisivos: a espécie estudada, a dose empregada, o desfecho avaliado e o contexto clínico em que a intervenção foi testada.
A transposição acrítica desse conteúdo para a medicina veterinária de pequenos animais apresenta riscos concretos. Cães e gatos diferem de humanos em fisiologia digestiva, composição da microbiota, metabolismo de aminoácidos e, sobretudo, no volume e na qualidade da evidência disponível. Felinos, em particular, são carnívoros obrigatórios com particularidades metabólicas bem documentadas, incluindo maiores perdas nitrogenadas endógenas e exigências elevadas de aminoácidos específicos.
Este trabalho tem como objetivo revisar criticamente a evidência sobre glutamina, integridade da barreira intestinal e disbiose em cães e gatos, com atenção especial ao contexto de imunossupressão viral felina, e propor um raciocínio clínico integrado para o uso racional desse aminoácido na prática veterinária.
2 FUNDAMENTOS: GLUTAMINA E O ENTERÓCITO
A glutamina exerce múltiplas funções na mucosa intestinal. É substrato energético primário dos enterócitos, participa da síntese de nucleotídeos e de glutationa, e atua na regulação da expressão de proteínas de junção estreita, incluindo ocludina, claudinas e a proteína de zonamento ZO-1. Essas junções constituem o principal determinante da permeabilidade paracelular e, portanto, da competência da barreira epitelial.
Além do efeito estrutural, a glutamina modula vias de sinalização inflamatória, com supressão da ativação do fator nuclear kappa B (NF-kB), e protege as células epiteliais contra apoptose e estresse oxidativo. Em modelos experimentais, a depleção de glutamina associa-se a aumento da permeabilidade intestinal, atrofia vilositária e maior translocação bacteriana.
Kim e Kim, em revisão publicada no International Journal of Molecular Sciences, sintetizam esse conjunto de mecanismos e destacam que a suplementação de glutamina tem sido investigada em contextos de estresse metabólico grave, incluindo trauma, sepse e doenças inflamatórias intestinais. Rao, em artigo dedicado especificamente à proteção das junções estreitas, descreve que o efeito protetor da glutamina sobre a barreira mucosa se relaciona diretamente à preservação da integridade dessas junções.
É importante distinguir, contudo, entre plausibilidade mecanística e eficácia clínica demonstrada. Os mecanismos descritos são robustos e reprodutíveis em modelos experimentais, mas a tradução para desfechos clínicos em espécies veterinárias exige estudos específicos, com doses, vias de administração e populações adequadamente definidas.
3 DISBIOSE: CONCEITO E RELEVÂNCIA EM PEQUENOS ANIMAIS
A disbiose designa o desequilíbrio da composição e da função da microbiota intestinal. Não se trata apenas de alteração na abundância relativa de determinados táxons, mas de modificação dos perfis metabólicos microbianos, com consequências sobre a produção de ácidos graxos de cadeia curta, o metabolismo de ácidos biliares e a modulação imunológica local.
Em cães e gatos, a disbiose está associada a diarreia crônica e a enteropatia crônica, condições de etiologia heterogênea e diagnóstico desafiador. A relação entre disbiose e inflamação mucosa é bidirecional: a inflamação altera o ambiente luminal e a composição microbiana, enquanto a microbiota alterada perpetua a resposta inflamatória e compromete a barreira epitelial.
A barreira intestinal deve ser compreendida como estrutura funcional integrada, composta por muco, junções estreitas, células epiteliais e tecido linfoide associado ao intestino (GALT). A falha de qualquer um desses componentes aumenta a permeabilidade a toxinas e patógenos, com ativação inflamatória sistêmica secundária.
Salavati Schmitz, em revisão publicada no Veterinary Record, analisa o uso de prebióticos, probióticos e pós-bióticos no manejo de distúrbios gastrointestinais em cães e gatos, destacando o potencial de redução do uso de antimicrobianos, mas também a necessidade de interpretação criteriosa da evidência disponível. Isidori, Corbee e Trabalza-Marinucci, em revisão sobre estratégias não farmacológicas na enteropatia inflamatória crônica canina, situam a integridade da barreira intestinal e a inflamação mucosa como alvos terapêuticos centrais, ao lado da modulação da microbiota.
No contexto felino, Drut e colaboradores revisam a microbiota intestinal de gatos com doença inflamatória intestinal e linfoma intestinal de baixo grau, condições que compartilham mecanismos com a doença inflamatória intestinal humana e nas quais o desequilíbrio microbiano parece desempenhar papel relevante. Makielski e colaboradores, em revisão narrativa sobre terapias para enteropatias crônicas, demonstram que a base de evidência é substancialmente maior em cães do que em gatos, sendo as dietas gastrointestinais terapêuticas e os glicocorticoides as intervenções com melhor sustentação em felinos.
4 EVIDÊNCIA EM CÃES
A base de evidência canina, embora ainda limitada, é a mais consistente na veterinária. O estudo mais relevante disponível é o ensaio clínico randomizado conduzido por Melo e colaboradores na Universidade Estadual Paulista, campus de Botucatu, publicado em Topics in Companion Animal Medicine.
Os autores avaliaram 20 cães com parvovirose canina tipo 2, distribuídos aleatoriamente em dois grupos. O grupo tratado recebeu glutamina na dose de 500 mg/kg/dia por via oral, associada a alimentação ad libitum, enquanto o grupo controle recebeu placebo nas mesmas condições de alimentação. Os desfechos incluíram duração da diarreia, escore fecal, tempo até melhora clínica, duração da hospitalização e mortalidade.
Os resultados mostraram redução significativa da duração da diarreia no grupo glutamina, com média de 2,4 dias, contra 4,9 dias no grupo controle. O escore fecal também foi superior no grupo tratado, com mediana de 5, contra 6,5 no controle. Não houve mortes no grupo glutamina, enquanto o grupo controle registrou 10% de mortalidade, correspondente a um animal. Não foram observadas diferenças significativas quanto ao tempo até o início da alimentação espontânea, ao tempo até melhora clínica ou à duração da hospitalização.
Os próprios autores reconhecem limitações importantes. A amostra é pequena, com dez animais por grupo. Houve diferença significativa de idade entre os grupos, sendo o grupo glutamina composto por animais mais jovens, com média de 3,5 meses, contra 6,3 meses no controle. Além disso, os níveis de albumina eram menores no grupo tratado na avaliação inicial, o que pode refletir diferenças de gravidade ou de estado nutricional na admissão. Tais fatores limitam a interpretação causal dos achados, ainda que o desfecho clínico observado seja relevante e justifique investigação adicional.
Outros estudos contribuem para o racional fisiopatológico. Mohr e colaboradores demonstraram, em cães com enterite parvoviral grave, que a nutrição enteral precoce influencia a permeabilidade intestinal, a perda proteica intestinal e o desfecho clínico, reforçando a importância da integridade da barreira na recuperação. Estudo publicado no American Journal of Veterinary Research avaliou a permeabilidade gastrointestinal e a capacidade absortiva mucosa em cães com enteropatia crônica, confirmando que a disfunção de barreira é mensurável nessa população. Ohno e colaboradores, em modelo experimental com cães conscientes, observaram que a glutamina reduz a duração do íleo pós-operatório após cirurgia abdominal, sugerindo efeito sobre a motilidade e a recuperação funcional intestinal.
Em conjunto, esses estudos sustentam plausibilidade e sinal de benefício, mas não permitem extrapolação para protocolos padronizados em enteropatia crônica canina, contexto em que a glutamina não foi avaliada em ensaios randomizados.
5 EVIDÊNCIA EM GATOS E O CONTEXTO FeLV+
A situação felina é substancialmente distinta. Não foram identificados ensaios clínicos randomizados avaliando suplementação de glutamina em gatos com enteropatia crônica, disbiose ou qualquer outra condição gastrointestinal. A maior parte do conhecimento aplicado à espécie é extrapolada de outras populações, o que impõe limitações evidentes.
A evidência disponível é indireta. Kathrani e colaboradores, em estudo metabolômico publicado no Scientific Reports, avaliaram gatos com enteropatia crônica submetidos a dieta de proteína hidrolisada. Na coorte de Bristol, a glutamina plasmática na admissão figurou entre os metabólitos preditivos de desfecho, ao lado de betaína, glicerol e alanina. Esse achado não se replicou na coorte do Royal Veterinary College, e os próprios autores atribuem a divergência a diferenças de gravidade, heterogeneidade da doença e tamanho amostral reduzido. O dado sugere valor da glutamina como marcador metabólico, não como intervenção terapêutica estabelecida.
No que se refere ao vírus da leucemia felina, trata-se de retrovírus oncogênico associado a imunossupressão, anemia e linfoma. Rolph e Cavanaugh, em revisão sobre causas infecciosas de neoplasia em gatos, situam o FeLV entre os primeiros agentes reconhecidos como oncogênicos na espécie. A imunossupressão viral compromete a mucosa intestinal e o GALT, favorecendo disbiose, translocação bacteriana e infecções oportunistas. Buchmann e colaboradores demonstraram associação significativa entre infecção por FeLV e maior suscetibilidade a Bartonella henselae em gatos, evidenciando o impacto da imunossupressão viral sobre a competência imunológica mucosal.
Nesse cenário, a suplementação de glutamina exige análise de risco-benefício particularmente cuidadosa. Células neoplásicas podem apresentar dependência de glutamina, fenômeno descrito na literatura oncológica como glutamine addiction. Muranaka e colaboradores, em revisão publicada em Cancers, discutem o equilíbrio delicado entre a suplementação, que sustenta a integridade intestinal e a função imune, e a possibilidade teórica de favorecer a tumorigênese. Fan e colaboradores, em revisão sobre metabolismo de glutamina como alvo terapêutico, descrevem o papel desse aminoácido como fonte de nitrogênio e carbono para células tumorais em proliferação.
É fundamental reconhecer que essa evidência provém de modelos humanos e experimentais. Não existem dados veterinários que estabeleçam segurança de suplementação de glutamina em gatos FeLV-positivos com risco elevado de linfoma. A decisão, portanto, deve ser individualizada, considerando estadiamento clínico, presença de neoplasia, estado nutricional e monitoramento longitudinal.
6 SEGURANÇA, DOSE E LIMITAÇÕES METODOLÓGICAS
A única dose documentada em ensaio clínico veterinário randomizado é a de 500 mg/kg/dia, empregada no estudo de parvovirose canina. Não há padronização de dose para enteropatia crônica em cães, nem para qualquer condição felina. Aspectos como biodisponibilidade, via de administração, fracionamento e duração do tratamento permanecem indefinidos na veterinária.
A evidência humana oferece um contraponto relevante ao entusiasmo. Abbasi e colaboradores, em revisão sistemática com metanálise publicada em Amino Acids, analisaram dez ensaios clínicos com 352 participantes e concluíram que a suplementação de glutamina não alterou significativamente a permeabilidade intestinal de forma global. O efeito somente se tornou significativo em doses superiores a 30 g/dia e por períodos inferiores a duas semanas. Esse resultado relativiza a expectativa de benefício universal e reforça a necessidade de ceticismo científico diante de recomendações genéricas.
Cruzat e colaboradores, em revisão abrangente sobre metabolismo e função imune da glutamina, destacam que, embora os efeitos imunológicos da suplementação estejam estabelecidos, persistem questões relevantes sobre desfechos in vivo em diferentes situações catabólicas. Holeček, ao revisar efeitos adversos de suplementos de aminoácidos, alerta que o aumento da ingestão de glutamina não é isento de risco, com potenciais efeitos sobre função renal, produção de amônia e competição com outros aminoácidos por transportadores de membrana.
Do ponto de vista prático, a formulação também impõe limitações: instabilidade da glutamina em solução, palatabilidade variável e custo de suplementação prolongada são fatores que influenciam a adesão do tutor e a viabilidade do protocolo.
7 INTEGRAÇÃO CLÍNICA: ONDE A GLUTAMINA SE INSERE
A glutamina deve ser compreendida como coadjuvante, jamais como substituta das intervenções com maior base de evidência. A hierarquia terapêutica na enteropatia crônica e na disbiose permanece centrada em quatro pilares: dieta terapêutica adequada, com emprego de proteína hidrolisada ou dieta de exclusão conforme o caso; manejo de bióticos com orientação profissional, incluindo prebióticos, probióticos, pós-bióticos e, em casos selecionados, transplante de microbiota fecal; controle da inflamação; e tratamento etiológico específico.
A revisão sistemática com metanálise de López Martí e colaboradores, publicada no Journal of Small Animal Practice, avaliou a eficácia de bióticos em gatos e concluiu que a certeza da evidência é baixa a muito baixa, com resultados favoráveis em parte dos ensaios com probióticos quanto à consistência fecal, mas sem sustentação robusta para recomendação indiscriminada. Whittemore e colaboradores demonstraram, em ensaio randomizado controlado, que a administração de simbiótico modula o microbioma e o metaboloma fecal de gatos tratados com clindamicina, com alterações em vias de ácidos graxos de cadeia curta, ácidos biliares e poliaminas. Wang e colaboradores observaram que a suplementação com pós-biótico melhorou a integridade da barreira intestinal em gatos, com redução de marcadores de permeabilidade como diaminoxidase e lipopolissacarídeo, além de aumento de imunoglobulina G e citocinas anti-inflamatórias.
Na perspectiva da medicina veterinária integrativa, a glutamina se soma a outros gradientes de informação que convergem para a restauração da homeostase. A farmacologia do sistema endocanabinoide oferece recursos para controle de inflamação crônica e imunomodulação; a nutrição clínica regenerativa, incluindo o estudo de peptídeos, busca favorecer processos de reparo tecidual; e a modulação da microbiota constitui o alicerce sobre o qual as demais intervenções se apoiam. A associação entre canabinoides e glutamina apresenta racional biológico, mas carece de estudos específicos de interação, o que deve ser considerado na prescrição.
8 CONSIDERAÇÕES FINAIS
A glutamina apresenta plausibilidade biológica sólida e evidência clínica promissora em cães, particularmente no contexto da parvovirose canina, onde um ensaio randomizado demonstrou redução da duração da diarreia e melhora do escore fecal. Esses achados, contudo, provêm de amostra pequena e apresentam limitações metodológicas que impedem generalização imediata.
Em disbiose crônica, a evidência permanece frágil em ambas as espécies. Em gatos, é praticamente ausente, restringindo-se a dados metabolômicos que posicionam a glutamina como marcador e não como terapia estabelecida. Em pacientes infectados pelo vírus da leucemia felina, o risco elevado de neoplasia impõe avaliação individualizada, uma vez que a segurança da suplementação nesse cenário não foi estabelecida.
A transposição direta de conteúdos de divulgação, especialmente os veiculados em redes sociais sem distinção de espécie, dose ou contexto clínico, é inadequada e potencialmente prejudicial. A prática veterinária baseada em evidências exige reconhecer os limites do conhecimento disponível e comunicá-los com transparência ao tutor.
Conclui-se que a glutamina deve ocupar posição coadjuvante, sobre uma base dietética adequada em proteína de alto valor biológico e manejo criterioso da microbiota, sempre com avaliação individualizada. Ensaios clínicos veterinários bem desenhados, com padronização de dose, desfechos e populações, são necessários para definir com precisão o papel desse aminoácido na clínica de pequenos animais.
Claudio Amichetti Junior — CRMV 75404 Pós em Nutrição Animal · Pós em Farmacologia · Pós em Cannabis Medicinal
REFERÊNCIAS
KIM, Min-Hyun; KIM, Hyeyoung. The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. International Journal of Molecular Sciences, v. 18, n. 5, p. 1051, 2017. DOI: 10.3390/ijms18051051.
RAO, RadhaKrishna; SAMAK, Geetha. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. Current Nutrition & Food Science, v. 8, n. 1, p. 47-54, 2012. DOI: 10.2174/1875044301205010047.
SALAVATI SCHMITZ, Silke. Evidence-based use of biotics in the management of gastrointestinal disorders in dogs and cats. Veterinary Record, 2024. DOI: 10.1002/vetr.4916.
ISIDORI, Marco; CORBEE, Ronald Jan; TRABALZA-MARINUCCI, Massimo. Nonpharmacological Treatment Strategies for the Management of Canine Chronic Inflammatory Enteropathy — A Narrative Review. Veterinary Sciences, v. 9, n. 2, p. 37, 2022. DOI: 10.3390/vetsci9020037.
DRUT, Amandine; MKAOUAR, Héla; KRIAA, Aïcha; MARIAULE, Vincent; AKERMI, Nizar; MÉRIC, Tristan; SÉNÉCAT, Odile; MAGUIN, Emmanuelle; HERNANDEZ, Juan L.; RHIMI, Moez. Gut microbiota in cats with inflammatory bowel disease and low-grade intestinal T-cell lymphoma. Frontiers in Microbiology, v. 15, p. 1346639, 2024. DOI: 10.3389/fmicb.2024.1346639.
MAKIELSKI, Kelly M.; CULLEN, Jonah N.; O'CONNOR, Annette M. Cormier; JERGENS, Albert E. Narrative review of therapies for chronic enteropathies in dogs and cats. Journal of Veterinary Internal Medicine, v. 33, n. 1, p. 11-22, 2019. DOI: 10.1111/jvim.15345.
MELO, Alice Madeira Campos; GHEDIN, Victória; ROMANO, Felipe Saab; DOS SANTOS, Natalia Ribeiro; PELLEGRI, Lara Alice Pagura; ICHIKAWA, Ricardo Shoiti; HUSSNI, Maria Fernanda; PAES, Antônio Carlos; GUIMARÃES-OKAMOTO, Priscylla Tatiana Chalfun; RAHAL, Sheila Canevese; MELCHERT, Alessandra. Oral glutamine supplementation in dogs infected with canine parvovirus type 2. Topics in Companion Animal Medicine, v. 70, p. 101040, 2026. DOI: 10.1016/j.tcam.2025.101040.
MOHR, Albert J.; LEISEWITZ, Andrew L.; JACOBSON, Linda S.; STEINER, Jörg M.; RUAUX, Craig G. Effect of Early Enteral Nutrition on Intestinal Permeability, Intestinal Protein Loss, and Outcome in Dogs with Severe Parvoviral Enteritis. Journal of Veterinary Internal Medicine, v. 17, n. 6, 2003. DOI: 10.1111/j.1939-1676.2003.tb02516.x.
Evaluation of gastrointestinal permeability and mucosal absorptive capacity in dogs with chronic enteropathy. American Journal of Veterinary Research, v. 67, n. 3, p. 479, 2006.
OHNO, Tetsuro; MOCHIKI, Erito; ANDO, Hiroyuki; FUKASAWA, Takaharu; TOYOMASU, Yoshitaka; OGATA, Kyoichi; AIHARA, Ryuusuke; ASAO, Takayuki; KUWANO, Hiroyuki. Glutamine Decreases the Duration of Postoperative Ileus After Abdominal Surgery: An Experimental Study of Conscious Dogs. Digestive Diseases and Sciences, 2008. DOI: 10.1007/s10620-008-0478-5.
KATHRANI, Aarti; YEN, Sandi; HALL, Edward J.; SWANN, Jonathan Richard. The effects of a hydrolyzed protein diet on the plasma, fecal and urine metabolome in cats with chronic enteropathy. Scientific Reports, v. 13, p. 19979, 2023. DOI: 10.1038/s41598-023-47334-y.
ROLPH, Kerry E.; CAVANAUGH, Ryan Patrick. Infectious Causes of Neoplasia in the Domestic Cat. Veterinary Sciences, v. 9, n. 9, p. 467, 2022. DOI: 10.3390/vetsci9090467.
BUCHMANN, Alexandra U.; KERSHAW, Olivia; KEMPF, Volkhard A. J.; GRUBER, Achim D. Does a Feline Leukemia Virus Infection Pave the Way for Bartonella henselae Infection in Cats? Journal of Clinical Microbiology, v. 48, n. 9, 2010. DOI: 10.1128/JCM.00750-10.
MURANAKA, Hayato; AKINSOLA, Rasaq; BILLET, Sandrine; PANDOL, Stephen Jacob; HENDIFAR, Andrew Eugene; BHOWMICK, Neil A.; GONG, Jun. Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention. Cancers, v. 16, n. 5, p. 1057, 2024. DOI: 10.3390/cancers16051057.
FAN, Yuxin; HAN, Xue; LI, Zhimin; HUO, Mingge; GAO, Hongxia; GUAN, Xingang. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment. Frontiers in Pharmacology, v. 15, p. 1345522, 2024. DOI: 10.3389/fphar.2024.1345522.
ABBASI, Fatemeh; HAGHIGHAT LARI, Mohammad Mehdi; KHOSRAVI, Gholamreza Reza; MANSOURI, Elahe; PAYANDEH, Nastaran; MILAJERDI, Alireza. A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults. Amino Acids, 2024. DOI: 10.1007/s00726-024-03420-7.
CRUZAT, Vínicius Fernandes; ROGERO, Marcelo Macedo; KEANE, Kevin Noel; CURI, Rui; NEWSHOLME, Philip. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, v. 10, n. 11, p. 1564, 2018. DOI: 10.3390/nu10111564.
HOLEČEK, Milan. Side Effects of Amino Acid Supplements. Physiological Research, v. 71, n. 1, p. 29-45, 2022. DOI: 10.33549/physiolres.934790.
LÓPEZ MARTÍ, Á.; MONTERO PALMA, C.; LÓPEZ MARTÍ, H.; RANCHAL SÁNCHEZ, A. Efficacy of probiotic, prebiotic, synbiotic and postbiotic supplementation on gastrointestinal health in cats: systematic review and meta-analysis. Journal of Small Animal Practice, v. 66, n. 4, p. 219-232, 2025. DOI: 10.1111/jsap.13822.
WHITTEMORE, Jacqueline C.; STOKES, Jennifer E.; PRICE, Joshua M.; SUCHODOLSKI, Jan S. Effects of a synbiotic on the fecal microbiome and metabolomic profiles of healthy research cats administered clindamycin: a randomized, controlled trial. Gut Microbes, v. 10, n. 4, p. 521-539, 2019. DOI: 10.1080/19490976.2018.1560754.
WANG, Weiwei; MIAO, Chengyi; CHEN, Qianqian; WANG, Longjiao; CHANG, Xiaohan; ZHAO, Lili; MA, Wenqiang; LEI, Shanyu; MA, Mengyao; ZHANG, Yuqiang; CHEN, Shuxing; CHEN, Lishui; WANG, Ran; GE, Shaoyang; XIONG, Wei. Postbiotic supplementation promotes gut barrier integrity and immune balance in cats via microbiota modulation. Frontiers in Microbiology, v. 16, p. 1692845, 2025. DOI: 10.3389/fmicb.2025.1692845.
YANG, Benlu; ZHONG, Shengwei; WANG, Jue; YU, Wanting. Dietary Modulation of the Gut Microbiota in Dogs and Cats and Its Role in Disease Management. Microorganisms, v. 13, n. 12, p. 2669, 2025. DOI: 10.3390/microorganisms13122669.
Glutamine, Intestinal Barrier and Dysbiosis in Dogs and Cats: From Human Evidence to Integrative Veterinary Clinical Practice
Claudio Amichetti Junior — CRMV 75404 Postgraduate in Animal Nutrition · Postgraduate in Pharmacology · Postgraduate in Medicinal Cannabis
ABSTRACT
Glutamine is the most abundant free amino acid in the body and the main energy substrate for enterocytes, playing a central role in maintaining intestinal barrier integrity. Interest in its supplementation has grown from human health communication, often presented in simplified form and without species distinction. This narrative review aims to critically analyze the available evidence on glutamine, intestinal barrier and dysbiosis in dogs and cats, including the context of feline viral immunosuppression. Indexed databases were consulted, prioritizing clinical trials, systematic reviews and mechanistic studies. In dogs, a randomized clinical trial in canine parvovirus demonstrated a significant reduction in diarrhea duration with oral glutamine at 500 mg/kg/day, albeit with relevant methodological limitations. In cats, no clinical trials of supplementation in chronic enteropathy or dysbiosis were identified, and the available evidence is indirect, derived from metabolomic analyses. In feline leukemia virus-infected patients, the elevated risk of neoplasia imposes additional caution, since tumor cells may present glutamine dependency. It is concluded that glutamine should be positioned as an adjuvant on an adequate dietary basis and microbiota management, never as a substitute for specific therapy, and that well-designed veterinary clinical trials are needed.
Keywords: glutamine; intestinal barrier; dysbiosis; chronic enteropathy; veterinary nutrition.
1 INTRODUCTION
Glutamine is the most abundant free amino acid in plasma and performs functions that go beyond its traditional classification as a non-essential amino acid. Under physiological conditions of catabolic stress, its availability may become limiting, which justifies the designation of conditionally essential amino acid. The gastrointestinal tract consumes a substantial portion of circulating glutamine, using it as a preferential energy source for enterocytes and as a precursor for nucleotides, glutathione and other metabolites essential to epithelial renewal.
In recent decades, this knowledge has consolidated in the clinical human nutrition literature and has circulated widely in consumer-facing content, including social media, where glutamine is frequently presented as a generic resource to "improve gut health and boost immunity." This simplified communication, although didactic, tends to suppress decisive elements: the species studied, the dose employed, the outcome assessed and the clinical context in which the intervention was tested.
The uncritical transposition of this content into small animal veterinary medicine carries concrete risks. Dogs and cats differ from humans in digestive physiology, microbiota composition, amino acid metabolism and, above all, in the volume and quality of available evidence. Cats, in particular, are obligate carnivores with well-documented metabolic particularities, including greater endogenous nitrogen losses and high requirements for specific amino acids.
This work aims to critically review the evidence on glutamine, intestinal barrier integrity and dysbiosis in dogs and cats, with special attention to the context of feline viral immunosuppression, and to propose an integrated clinical reasoning for the rational use of this amino acid in veterinary practice.
2 FUNDAMENTALS: GLUTAMINE AND THE ENTEROCYTE
Glutamine exerts multiple functions in the intestinal mucosa. It is the primary energy substrate for enterocytes, participates in the synthesis of nucleotides and glutathione, and regulates the expression of tight junction proteins, including occludin, claudins and the zonula occludens protein ZO-1. These junctions constitute the main determinant of paracellular permeability and, therefore, of epithelial barrier competence.
Beyond the structural effect, glutamine modulates inflammatory signaling pathways, suppressing activation of nuclear factor kappa B (NF-kB), and protects epithelial cells against apoptosis and oxidative stress. In experimental models, glutamine depletion is associated with increased intestinal permeability, villous atrophy and greater bacterial translocation.
Kim and Kim, in a review published in the International Journal of Molecular Sciences, synthesize this set of mechanisms and highlight that glutamine supplementation has been investigated in contexts of severe metabolic stress, including trauma, sepsis and inflammatory bowel diseases. Rao, in an article specifically dedicated to tight junction protection, describes that the protective effect of glutamine on the mucosal barrier relates directly to the preservation of tight junction integrity.
It is important, however, to distinguish between mechanistic plausibility and demonstrated clinical efficacy. The mechanisms described are robust and reproducible in experimental models, but translation into clinical outcomes in veterinary species requires specific studies with adequately defined doses, routes of administration and populations.
3 DYSBIOSIS: CONCEPT AND RELEVANCE IN SMALL ANIMALS
Dysbiosis designates the imbalance of intestinal microbiota composition and function. It is not merely a change in the relative abundance of certain taxa, but a modification of microbial metabolic profiles, with consequences for short-chain fatty acid production, bile acid metabolism and local immune modulation.
In dogs and cats, dysbiosis is associated with chronic diarrhea and chronic enteropathy, conditions of heterogeneous etiology and challenging diagnosis. The relationship between dysbiosis and mucosal inflammation is bidirectional: inflammation alters the luminal environment and microbial composition, while altered microbiota perpetuates the inflammatory response and compromises the epithelial barrier.
The intestinal barrier should be understood as an integrated functional structure, composed of mucus, tight junctions, epithelial cells and gut-associated lymphoid tissue (GALT). Failure of any of these components increases permeability to toxins and pathogens, with secondary systemic inflammatory activation.
Salavati Schmitz, in a review published in the Veterinary Record, analyzes the use of prebiotics, probiotics and postbiotics in the management of gastrointestinal disorders in dogs and cats, highlighting the potential to reduce antimicrobial use, but also the need for careful interpretation of the available evidence. Isidori, Corbee and Trabalza-Marinucci, in a review on non-pharmacological strategies in canine chronic inflammatory enteropathy, position intestinal barrier integrity and mucosal inflammation as central therapeutic targets, alongside microbiota modulation.
In the feline context, Drut and colleagues review the intestinal microbiota of cats with inflammatory bowel disease and low-grade intestinal lymphoma, conditions that share mechanisms with human inflammatory bowel disease and in which microbial imbalance appears to play a relevant role. Makielski and colleagues, in a narrative review on therapies for chronic enteropathies, demonstrate that the evidence base is substantially larger in dogs than in cats, with therapeutic gastrointestinal diets and glucocorticoids being the interventions with the best support in felines.
4 EVIDENCE IN DOGS
The canine evidence base, although still limited, is the most consistent in veterinary medicine. The most relevant available study is the randomized clinical trial conducted by Melo and colleagues at São Paulo State University, Botucatu campus, published in Topics in Companion Animal Medicine.
The authors evaluated 20 dogs with canine parvovirus type 2, randomly assigned to two groups. The treated group received glutamine at 500 mg/kg/day orally, combined with ad libitum feeding, while the control group received placebo under the same feeding conditions. Outcomes included diarrhea duration, fecal score, time to clinical improvement, length of hospitalization and mortality.
Results showed a significant reduction in diarrhea duration in the glutamine group, with a mean of 2.4 days, versus 4.9 days in the control group. Fecal score was also better in the treated group, with a median of 5, versus 6.5 in the control. There were no deaths in the glutamine group, while the control group recorded 10% mortality, corresponding to one animal. No significant differences were observed regarding time to spontaneous feeding, time to clinical improvement or length of hospitalization.
The authors themselves acknowledge important limitations. The sample is small, with ten animals per group. There was a significant age difference between groups, with the glutamine group composed of younger animals, mean 3.5 months, versus 6.3 months in the control. In addition, albumin levels were lower in the treated group at initial assessment, which may reflect differences in severity or nutritional status on admission. These factors limit causal interpretation of the findings, although the observed clinical outcome is relevant and justifies further investigation.
Other studies contribute to the pathophysiological rationale. Mohr and colleagues demonstrated, in dogs with severe parvoviral enteritis, that early enteral nutrition influences intestinal permeability, intestinal protein loss and clinical outcome, reinforcing the importance of barrier integrity in recovery. A study published in the American Journal of Veterinary Research evaluated gastrointestinal permeability and mucosal absorptive capacity in dogs with chronic enteropathy, confirming that barrier dysfunction is measurable in this population. Ohno and colleagues, in an experimental model with conscious dogs, observed that glutamine reduces the duration of postoperative ileus after abdominal surgery, suggesting an effect on motility and functional intestinal recovery.
Taken together, these studies support plausibility and a signal of benefit, but do not allow extrapolation to standardized protocols in canine chronic enteropathy, a context in which glutamine has not been evaluated in randomized trials.
5 EVIDENCE IN CATS AND THE FeLV+ CONTEXT
The feline situation is substantially different. No randomized clinical trials evaluating glutamine supplementation in cats with chronic enteropathy, dysbiosis or any other gastrointestinal condition were identified. Most of the knowledge applied to the species is extrapolated from other populations, which imposes evident limitations.
The available evidence is indirect. Kathrani and colleagues, in a metabolomic study published in Scientific Reports, evaluated cats with chronic enteropathy undergoing a hydrolyzed protein diet. In the Bristol cohort, plasma glutamine on admission was among the metabolites predictive of outcome, alongside betaine, glycerol and alanine. This finding did not replicate in the Royal Veterinary College cohort, and the authors themselves attribute the divergence to differences in severity, disease heterogeneity and small sample size. The data suggest value of glutamine as a metabolic marker, not as an established therapeutic intervention.
Regarding feline leukemia virus, it is an oncogenic retrovirus associated with immunosuppression, anemia and lymphoma. Rolph and Cavanaugh, in a review on infectious causes of neoplasia in cats, position FeLV among the first agents recognized as oncogenic in the species. Viral immunosuppression compromises the intestinal mucosa and GALT, favoring dysbiosis, bacterial translocation and opportunistic infections. Buchmann and colleagues demonstrated a significant association between FeLV infection and greater susceptibility to Bartonella henselae in cats, evidencing the impact of viral immunosuppression on mucosal immune competence.
In this scenario, glutamine supplementation requires particularly careful risk-benefit analysis. Neoplastic cells may present glutamine dependency, a phenomenon described in the oncology literature as glutamine addiction. Muranaka and colleagues, in a review published in Cancers, discuss the delicate balance between supplementation, which supports intestinal integrity and immune function, and the theoretical possibility of favoring tumorigenesis. Fan and colleagues, in a review on glutamine metabolism as a therapeutic target, describe the role of this amino acid as a nitrogen and carbon source for proliferating tumor cells.
It is essential to recognize that this evidence comes from human and experimental models. There are no veterinary data establishing the safety of glutamine supplementation in FeLV-positive cats at high risk of lymphoma. The decision, therefore, must be individualized, considering clinical staging, presence of neoplasia, nutritional status and longitudinal monitoring.
6 SAFETY, DOSE AND METHODOLOGICAL LIMITATIONS
The only dose documented in a randomized veterinary clinical trial is 500 mg/kg/day, employed in the canine parvovirus study. There is no dose standardization for chronic enteropathy in dogs, nor for any feline condition. Aspects such as bioavailability, route of administration, fractionation and treatment duration remain undefined in veterinary medicine.
Human evidence offers a relevant counterpoint to enthusiasm. Abbasi and colleagues, in a systematic review with meta-analysis published in Amino Acids, analyzed ten clinical trials with 352 participants and concluded that glutamine supplementation did not significantly alter intestinal permeability globally. The effect only became significant at doses above 30 g/day and for periods shorter than two weeks. This result relativizes the expectation of universal benefit and reinforces the need for scientific skepticism regarding generic recommendations.
Cruzat and colleagues, in a comprehensive review on glutamine metabolism and immune function, highlight that, although the immunological effects of supplementation are established, relevant questions remain about in vivo outcomes in different catabolic situations. Holeček, reviewing adverse effects of amino acid supplements, warns that increased glutamine intake is not risk-free, with potential effects on renal function, ammonia production and competition with other amino acids for membrane transporters.
From a practical standpoint, formulation also imposes limitations: glutamine instability in solution, variable palatability and the cost of prolonged supplementation are factors that influence owner adherence and protocol feasibility.
7 CLINICAL INTEGRATION: WHERE GLUTAMINE FITS
Glutamine should be understood as an adjuvant, never as a substitute for interventions with a stronger evidence base. The therapeutic hierarchy in chronic enteropathy and dysbiosis remains centered on four pillars: adequate therapeutic diet, using hydrolyzed protein or elimination diet as appropriate; biotics management with professional guidance, including prebiotics, probiotics, postbiotics and, in selected cases, fecal microbiota transplantation; inflammation control; and specific etiological treatment.
The systematic review with meta-analysis by López Martí and colleagues, published in the Journal of Small Animal Practice, evaluated the efficacy of biotics in cats and concluded that the certainty of evidence is low to very low, with favorable results in some probiotic trials regarding fecal consistency, but without robust support for indiscriminate recommendation. Whittemore and colleagues demonstrated, in a randomized controlled trial, that synbiotic administration modulates the fecal microbiome and metabolome of cats treated with clindamycin, with alterations in short-chain fatty acid, bile acid and polyamine pathways. Wang and colleagues observed that postbiotic supplementation improved intestinal barrier integrity in cats, with reduced permeability markers such as diamine oxidase and lipopolysaccharide, in addition to increased immunoglobulin G and anti-inflammatory cytokines.
From the perspective of integrative veterinary medicine, glutamine adds to other information gradients that converge toward restoring homeostasis. Endocannabinoid system pharmacology offers resources for chronic inflammation control and immunomodulation; regenerative clinical nutrition, including the study of peptides, seeks to favor tissue repair processes; and microbiota modulation constitutes the foundation on which other interventions rest. The association between cannabinoids and glutamine presents a biological rationale, but lacks specific interaction studies, which should be considered in prescribing.
8 FINAL CONSIDERATIONS
Glutamine presents solid biological plausibility and promising clinical evidence in dogs, particularly in the context of canine parvovirus, where a randomized trial demonstrated reduced diarrhea duration and improved fecal score. These findings, however, come from a small sample and present methodological limitations that prevent immediate generalization.
In chronic dysbiosis, the evidence remains fragile in both species. In cats, it is practically absent, restricted to metabolomic data that position glutamine as a marker rather than an established therapy. In feline leukemia virus-infected patients, the elevated risk of neoplasia imposes individualized assessment, since the safety of supplementation in this scenario has not been established.
The direct transposition of consumer-facing content, especially that disseminated on social media without distinction of species, dose or clinical context, is inadequate and potentially harmful. Evidence-based veterinary practice requires recognizing the limits of available knowledge and communicating them transparently to the owner.
It is concluded that glutamine should occupy an adjuvant position, on an adequate dietary basis in high biological value protein and careful microbiota management, always with individualized assessment. Well-designed veterinary clinical trials, with standardized doses, outcomes and populations, are needed to precisely define the role of this amino acid in small animal practice.
Claudio Amichetti Junior — CRMV 75404 Postgraduate in Animal Nutrition · Postgraduate in Pharmacology · Postgraduate in Medicinal Cannabis
REFERENCES
KIM, Min-Hyun; KIM, Hyeyoung. The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. International Journal of Molecular Sciences, v. 18, n. 5, p. 1051, 2017. DOI: 10.3390/ijms18051051.
RAO, RadhaKrishna; SAMAK, Geetha. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. Current Nutrition & Food Science, v. 8, n. 1, p. 47-54, 2012. DOI: 10.2174/1875044301205010047.
SALAVATI SCHMITZ, Silke. Evidence-based use of biotics in the management of gastrointestinal disorders in dogs and cats. Veterinary Record, 2024. DOI: 10.1002/vetr.4916.
ISIDORI, Marco; CORBEE, Ronald Jan; TRABALZA-MARINUCCI, Massimo. Nonpharmacological Treatment Strategies for the Management of Canine Chronic Inflammatory Enteropathy — A Narrative Review. Veterinary Sciences, v. 9, n. 2, p. 37, 2022. DOI: 10.3390/vetsci9020037.
DRUT, Amandine; MKAOUAR, Héla; KRIAA, Aïcha; MARIAULE, Vincent; AKERMI, Nizar; MÉRIC, Tristan; SÉNÉCAT, Odile; MAGUIN, Emmanuelle; HERNANDEZ, Juan L.; RHIMI, Moez. Gut microbiota in cats with inflammatory bowel disease and low-grade intestinal T-cell lymphoma. Frontiers in Microbiology, v. 15, p. 1346639, 2024. DOI: 10.3389/fmicb.2024.1346639.
MAKIELSKI, Kelly M.; CULLEN, Jonah N.; O'CONNOR, Annette M. Cormier; JERGENS, Albert E. Narrative review of therapies for chronic enteropathies in dogs and cats. Journal of Veterinary Internal Medicine, v. 33, n. 1, p. 11-22, 2019. DOI: 10.1111/jvim.15345.
MELO, Alice Madeira Campos; GHEDIN, Victória; ROMANO, Felipe Saab; DOS SANTOS, Natalia Ribeiro; PELLEGRI, Lara Alice Pagura; ICHIKAWA, Ricardo Shoiti; HUSSNI, Maria Fernanda; PAES, Antônio Carlos; GUIMARÃES-OKAMOTO, Priscylla Tatiana Chalfun; RAHAL, Sheila Canevese; MELCHERT, Alessandra. Oral glutamine supplementation in dogs infected with canine parvovirus type 2. Topics in Companion Animal Medicine, v. 70, p. 101040, 2026. DOI: 10.1016/j.tcam.2025.101040.
MOHR, Albert J.; LEISEWITZ, Andrew L.; JACOBSON, Linda S.; STEINER, Jörg M.; RUAUX, Craig G. Effect of Early Enteral Nutrition on Intestinal Permeability, Intestinal Protein Loss, and Outcome in Dogs with Severe Parvoviral Enteritis. Journal of Veterinary Internal Medicine, v. 17, n. 6, 2003. DOI: 10.1111/j.1939-1676.2003.tb02516.x.
Evaluation of gastrointestinal permeability and mucosal absorptive capacity in dogs with chronic enteropathy. American Journal of Veterinary Research, v. 67, n. 3, p. 479, 2006.
OHNO, Tetsuro; MOCHIKI, Erito; ANDO, Hiroyuki; FUKASAWA, Takaharu; TOYOMASU, Yoshitaka; OGATA, Kyoichi; AIHARA, Ryuusuke; ASAO, Takayuki; KUWANO, Hiroyuki. Glutamine Decreases the Duration of Postoperative Ileus After Abdominal Surgery: An Experimental Study of Conscious Dogs. Digestive Diseases and Sciences, 2008. DOI: 10.1007/s10620-008-0478-5.
KATHRANI, Aarti; YEN, Sandi; HALL, Edward J.; SWANN, Jonathan Richard. The effects of a hydrolyzed protein diet on the plasma, fecal and urine metabolome in cats with chronic enteropathy. Scientific Reports, v. 13, p. 19979, 2023. DOI: 10.1038/s41598-023-47334-y.
ROLPH, Kerry E.; CAVANAUGH, Ryan Patrick. Infectious Causes of Neoplasia in the Domestic Cat. Veterinary Sciences, v. 9, n. 9, p. 467, 2022. DOI: 10.3390/vetsci9090467.
BUCHMANN, Alexandra U.; KERSHAW, Olivia; KEMPF, Volkhard A. J.; GRUBER, Achim D. Does a Feline Leukemia Virus Infection Pave the Way for Bartonella henselae Infection in Cats? Journal of Clinical Microbiology, v. 48, n. 9, 2010. DOI: 10.1128/JCM.00750-10.
MURANAKA, Hayato; AKINSOLA, Rasaq; BILLET, Sandrine; PANDOL, Stephen Jacob; HENDIFAR, Andrew Eugene; BHOWMICK, Neil A.; GONG, Jun. Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention. Cancers, v. 16, n. 5, p. 1057, 2024. DOI: 10.3390/cancers16051057.
FAN, Yuxin; HAN, Xue; LI, Zhimin; HUO, Mingge; GAO, Hongxia; GUAN, Xingang. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment. Frontiers in Pharmacology, v. 15, p. 1345522, 2024. DOI: 10.3389/fphar.2024.1345522.
ABBASI, Fatemeh; HAGHIGHAT LARI, Mohammad Mehdi; KHOSRAVI, Gholamreza Reza; MANSOURI, Elahe; PAYANDEH, Nastaran; MILAJERDI, Alireza. A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults. Amino Acids, 2024. DOI: 10.1007/s00726-024-03420-7.
CRUZAT, Vínicius Fernandes; ROGERO, Marcelo Macedo; KEANE, Kevin Noel; CURI, Rui; NEWSHOLME, Philip. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, v. 10, n. 11, p. 1564, 2018. DOI: 10.3390/nu10111564.
HOLEČEK, Milan. Side Effects of Amino Acid Supplements. Physiological Research, v. 71, n. 1, p. 29-45, 2022. DOI: 10.33549/physiolres.934790.
LÓPEZ MARTÍ, Á.; MONTERO PALMA, C.; LÓPEZ MARTÍ, H.; RANCHAL SÁNCHEZ, A. Efficacy of probiotic, prebiotic, synbiotic and postbiotic supplementation on gastrointestinal health in cats: systematic review and meta-analysis. Journal of Small Animal Practice, v. 66, n. 4, p. 219-232, 2025. DOI: 10.1111/jsap.13822.
WHITTEMORE, Jacqueline C.; STOKES, Jennifer E.; PRICE, Joshua M.; SUCHODOLSKI, Jan S. Effects of a synbiotic on the fecal microbiome and metabolomic profiles of healthy research cats administered clindamycin: a randomized, controlled trial. Gut Microbes, v. 10, n. 4, p. 521-539, 2019. DOI: 10.1080/19490976.2018.1560754.
WANG, Weiwei; MIAO, Chengyi; CHEN, Qianqian; WANG, Longjiao; CHANG, Xiaohan; ZHAO, Lili; MA, Wenqiang; LEI, Shanyu; MA, Mengyao; ZHANG, Yuqiang; CHEN, Shuxing; CHEN, Lishui; WANG, Ran; GE, Shaoyang; XIONG, Wei. Postbiotic supplementation promotes gut barrier integrity and immune balance in cats via microbiota modulation. Frontiers in Microbiology, v. 16, p. 1692845, 2025. DOI: 10.3389/fmicb.2025.1692845.
YANG, Benlu; ZHONG, Shengwei; WANG, Jue; YU, Wanting. Dietary Modulation of the Gut Microbiota in Dogs and Cats and Its Role in Disease Management. Microorganisms, v. 13, n. 12, p. 2669, 2025. DOI: 10.3390/microorganisms13122669.
Glutamine, Intestinal Barrier and Dysbiosis in Dogs and Cats: From Human Evidence to Integrative Veterinary Clinical Practice
Claudio Amichetti Junior — CRMV 75404 Postgraduate in Animal Nutrition · Postgraduate in Pharmacology · Postgraduate in Medicinal Cannabis
ABSTRACT
Glutamine is the most abundant free amino acid in the body and the main energy substrate for enterocytes, playing a central role in maintaining intestinal barrier integrity. Interest in its supplementation has grown from human health communication, often presented in simplified form and without species distinction. This narrative review aims to critically analyze the available evidence on glutamine, intestinal barrier and dysbiosis in dogs and cats, including the context of feline viral immunosuppression. Indexed databases were consulted, prioritizing clinical trials, systematic reviews and mechanistic studies. In dogs, a randomized clinical trial in canine parvovirus demonstrated a significant reduction in diarrhea duration with oral glutamine at 500 mg/kg/day, albeit with relevant methodological limitations. In cats, no clinical trials of supplementation in chronic enteropathy or dysbiosis were identified, and the available evidence is indirect, derived from metabolomic analyses. In feline leukemia virus-infected patients, the elevated risk of neoplasia imposes additional caution, since tumor cells may present glutamine dependency. It is concluded that glutamine should be positioned as an adjuvant on an adequate dietary basis and microbiota management, never as a substitute for specific therapy, and that well-designed veterinary clinical trials are needed.
Keywords: glutamine; intestinal barrier; dysbiosis; chronic enteropathy; veterinary nutrition.
1 INTRODUCTION
Glutamine is the most abundant free amino acid in plasma and performs functions that go beyond its traditional classification as a non-essential amino acid. Under physiological conditions of catabolic stress, its availability may become limiting, which justifies the designation of conditionally essential amino acid. The gastrointestinal tract consumes a substantial portion of circulating glutamine, using it as a preferential energy source for enterocytes and as a precursor for nucleotides, glutathione and other metabolites essential to epithelial renewal.
In recent decades, this knowledge has consolidated in the clinical human nutrition literature and has circulated widely in consumer-facing content, including social media, where glutamine is frequently presented as a generic resource to "improve gut health and boost immunity." This simplified communication, although didactic, tends to suppress decisive elements: the species studied, the dose employed, the outcome assessed and the clinical context in which the intervention was tested.
The uncritical transposition of this content into small animal veterinary medicine carries concrete risks. Dogs and cats differ from humans in digestive physiology, microbiota composition, amino acid metabolism and, above all, in the volume and quality of available evidence. Cats, in particular, are obligate carnivores with well-documented metabolic particularities, including greater endogenous nitrogen losses and high requirements for specific amino acids.
This work aims to critically review the evidence on glutamine, intestinal barrier integrity and dysbiosis in dogs and cats, with special attention to the context of feline viral immunosuppression, and to propose an integrated clinical reasoning for the rational use of this amino acid in veterinary practice.
2 FUNDAMENTALS: GLUTAMINE AND THE ENTEROCYTE
Glutamine exerts multiple functions in the intestinal mucosa. It is the primary energy substrate for enterocytes, participates in the synthesis of nucleotides and glutathione, and regulates the expression of tight junction proteins, including occludin, claudins and the zonula occludens protein ZO-1. These junctions constitute the main determinant of paracellular permeability and, therefore, of epithelial barrier competence.
Beyond the structural effect, glutamine modulates inflammatory signaling pathways, suppressing activation of nuclear factor kappa B (NF-kB), and protects epithelial cells against apoptosis and oxidative stress. In experimental models, glutamine depletion is associated with increased intestinal permeability, villous atrophy and greater bacterial translocation.
Kim and Kim, in a review published in the International Journal of Molecular Sciences, synthesize this set of mechanisms and highlight that glutamine supplementation has been investigated in contexts of severe metabolic stress, including trauma, sepsis and inflammatory bowel diseases. Rao, in an article specifically dedicated to tight junction protection, describes that the protective effect of glutamine on the mucosal barrier relates directly to the preservation of tight junction integrity.
It is important, however, to distinguish between mechanistic plausibility and demonstrated clinical efficacy. The mechanisms described are robust and reproducible in experimental models, but translation into clinical outcomes in veterinary species requires specific studies with adequately defined doses, routes of administration and populations.
3 DYSBIOSIS: CONCEPT AND RELEVANCE IN SMALL ANIMALS
Dysbiosis designates the imbalance of intestinal microbiota composition and function. It is not merely a change in the relative abundance of certain taxa, but a modification of microbial metabolic profiles, with consequences for short-chain fatty acid production, bile acid metabolism and local immune modulation.
In dogs and cats, dysbiosis is associated with chronic diarrhea and chronic enteropathy, conditions of heterogeneous etiology and challenging diagnosis. The relationship between dysbiosis and mucosal inflammation is bidirectional: inflammation alters the luminal environment and microbial composition, while altered microbiota perpetuates the inflammatory response and compromises the epithelial barrier.
The intestinal barrier should be understood as an integrated functional structure, composed of mucus, tight junctions, epithelial cells and gut-associated lymphoid tissue (GALT). Failure of any of these components increases permeability to toxins and pathogens, with secondary systemic inflammatory activation.
Salavati Schmitz, in a review published in the Veterinary Record, analyzes the use of prebiotics, probiotics and postbiotics in the management of gastrointestinal disorders in dogs and cats, highlighting the potential to reduce antimicrobial use, but also the need for careful interpretation of the available evidence. Isidori, Corbee and Trabalza-Marinucci, in a review on non-pharmacological strategies in canine chronic inflammatory enteropathy, position intestinal barrier integrity and mucosal inflammation as central therapeutic targets, alongside microbiota modulation.
In the feline context, Drut and colleagues review the intestinal microbiota of cats with inflammatory bowel disease and low-grade intestinal lymphoma, conditions that share mechanisms with human inflammatory bowel disease and in which microbial imbalance appears to play a relevant role. Makielski and colleagues, in a narrative review on therapies for chronic enteropathies, demonstrate that the evidence base is substantially larger in dogs than in cats, with therapeutic gastrointestinal diets and glucocorticoids being the interventions with the best support in felines.
4 EVIDENCE IN DOGS
The canine evidence base, although still limited, is the most consistent in veterinary medicine. The most relevant available study is the randomized clinical trial conducted by Melo and colleagues at São Paulo State University, Botucatu campus, published in Topics in Companion Animal Medicine.
The authors evaluated 20 dogs with canine parvovirus type 2, randomly assigned to two groups. The treated group received glutamine at 500 mg/kg/day orally, combined with ad libitum feeding, while the control group received placebo under the same feeding conditions. Outcomes included diarrhea duration, fecal score, time to clinical improvement, length of hospitalization and mortality.
Results showed a significant reduction in diarrhea duration in the glutamine group, with a mean of 2.4 days, versus 4.9 days in the control group. Fecal score was also better in the treated group, with a median of 5, versus 6.5 in the control. There were no deaths in the glutamine group, while the control group recorded 10% mortality, corresponding to one animal. No significant differences were observed regarding time to spontaneous feeding, time to clinical improvement or length of hospitalization.
The authors themselves acknowledge important limitations. The sample is small, with ten animals per group. There was a significant age difference between groups, with the glutamine group composed of younger animals, mean 3.5 months, versus 6.3 months in the control. In addition, albumin levels were lower in the treated group at initial assessment, which may reflect differences in severity or nutritional status on admission. These factors limit causal interpretation of the findings, although the observed clinical outcome is relevant and justifies further investigation.
Other studies contribute to the pathophysiological rationale. Mohr and colleagues demonstrated, in dogs with severe parvoviral enteritis, that early enteral nutrition influences intestinal permeability, intestinal protein loss and clinical outcome, reinforcing the importance of barrier integrity in recovery. A study published in the American Journal of Veterinary Research evaluated gastrointestinal permeability and mucosal absorptive capacity in dogs with chronic enteropathy, confirming that barrier dysfunction is measurable in this population. Ohno and colleagues, in an experimental model with conscious dogs, observed that glutamine reduces the duration of postoperative ileus after abdominal surgery, suggesting an effect on motility and functional intestinal recovery.
Taken together, these studies support plausibility and a signal of benefit, but do not allow extrapolation to standardized protocols in canine chronic enteropathy, a context in which glutamine has not been evaluated in randomized trials.
5 EVIDENCE IN CATS AND THE FeLV+ CONTEXT
The feline situation is substantially different. No randomized clinical trials evaluating glutamine supplementation in cats with chronic enteropathy, dysbiosis or any other gastrointestinal condition were identified. Most of the knowledge applied to the species is extrapolated from other populations, which imposes evident limitations.
The available evidence is indirect. Kathrani and colleagues, in a metabolomic study published in Scientific Reports, evaluated cats with chronic enteropathy undergoing a hydrolyzed protein diet. In the Bristol cohort, plasma glutamine on admission was among the metabolites predictive of outcome, alongside betaine, glycerol and alanine. This finding did not replicate in the Royal Veterinary College cohort, and the authors themselves attribute the divergence to differences in severity, disease heterogeneity and small sample size. The data suggest value of glutamine as a metabolic marker, not as an established therapeutic intervention.
Regarding feline leukemia virus, it is an oncogenic retrovirus associated with immunosuppression, anemia and lymphoma. Rolph and Cavanaugh, in a review on infectious causes of neoplasia in cats, position FeLV among the first agents recognized as oncogenic in the species. Viral immunosuppression compromises the intestinal mucosa and GALT, favoring dysbiosis, bacterial translocation and opportunistic infections. Buchmann and colleagues demonstrated a significant association between FeLV infection and greater susceptibility to Bartonella henselae in cats, evidencing the impact of viral immunosuppression on mucosal immune competence.
In this scenario, glutamine supplementation requires particularly careful risk-benefit analysis. Neoplastic cells may present glutamine dependency, a phenomenon described in the oncology literature as glutamine addiction. Muranaka and colleagues, in a review published in Cancers, discuss the delicate balance between supplementation, which supports intestinal integrity and immune function, and the theoretical possibility of favoring tumorigenesis. Fan and colleagues, in a review on glutamine metabolism as a therapeutic target, describe the role of this amino acid as a nitrogen and carbon source for proliferating tumor cells.
It is essential to recognize that this evidence comes from human and experimental models. There are no veterinary data establishing the safety of glutamine supplementation in FeLV-positive cats at high risk of lymphoma. The decision, therefore, must be individualized, considering clinical staging, presence of neoplasia, nutritional status and longitudinal monitoring.
6 SAFETY, DOSE AND METHODOLOGICAL LIMITATIONS
The only dose documented in a randomized veterinary clinical trial is 500 mg/kg/day, employed in the canine parvovirus study. There is no dose standardization for chronic enteropathy in dogs, nor for any feline condition. Aspects such as bioavailability, route of administration, fractionation and treatment duration remain undefined in veterinary medicine.
Human evidence offers a relevant counterpoint to enthusiasm. Abbasi and colleagues, in a systematic review with meta-analysis published in Amino Acids, analyzed ten clinical trials with 352 participants and concluded that glutamine supplementation did not significantly alter intestinal permeability globally. The effect only became significant at doses above 30 g/day and for periods shorter than two weeks. This result relativizes the expectation of universal benefit and reinforces the need for scientific skepticism regarding generic recommendations.
Cruzat and colleagues, in a comprehensive review on glutamine metabolism and immune function, highlight that, although the immunological effects of supplementation are established, relevant questions remain about in vivo outcomes in different catabolic situations. Holeček, reviewing adverse effects of amino acid supplements, warns that increased glutamine intake is not risk-free, with potential effects on renal function, ammonia production and competition with other amino acids for membrane transporters.
From a practical standpoint, formulation also imposes limitations: glutamine instability in solution, variable palatability and the cost of prolonged supplementation are factors that influence owner adherence and protocol feasibility.
7 CLINICAL INTEGRATION: WHERE GLUTAMINE FITS
Glutamine should be understood as an adjuvant, never as a substitute for interventions with a stronger evidence base. The therapeutic hierarchy in chronic enteropathy and dysbiosis remains centered on four pillars: adequate therapeutic diet, using hydrolyzed protein or elimination diet as appropriate; biotics management with professional guidance, including prebiotics, probiotics, postbiotics and, in selected cases, fecal microbiota transplantation; inflammation control; and specific etiological treatment.
The systematic review with meta-analysis by López Martí and colleagues, published in the Journal of Small Animal Practice, evaluated the efficacy of biotics in cats and concluded that the certainty of evidence is low to very low, with favorable results in some probiotic trials regarding fecal consistency, but without robust support for indiscriminate recommendation. Whittemore and colleagues demonstrated, in a randomized controlled trial, that synbiotic administration modulates the fecal microbiome and metabolome of cats treated with clindamycin, with alterations in short-chain fatty acid, bile acid and polyamine pathways. Wang and colleagues observed that postbiotic supplementation improved intestinal barrier integrity in cats, with reduced permeability markers such as diamine oxidase and lipopolysaccharide, in addition to increased immunoglobulin G and anti-inflammatory cytokines.
From the perspective of integrative veterinary medicine, glutamine adds to other information gradients that converge toward restoring homeostasis. Endocannabinoid system pharmacology offers resources for chronic inflammation control and immunomodulation; regenerative clinical nutrition, including the study of peptides, seeks to favor tissue repair processes; and microbiota modulation constitutes the foundation on which other interventions rest. The association between cannabinoids and glutamine presents a biological rationale, but lacks specific interaction studies, which should be considered in prescribing.
8 FINAL CONSIDERATIONS
Glutamine presents solid biological plausibility and promising clinical evidence in dogs, particularly in the context of canine parvovirus, where a randomized trial demonstrated reduced diarrhea duration and improved fecal score. These findings, however, come from a small sample and present methodological limitations that prevent immediate generalization.
In chronic dysbiosis, the evidence remains fragile in both species. In cats, it is practically absent, restricted to metabolomic data that position glutamine as a marker rather than an established therapy. In feline leukemia virus-infected patients, the elevated risk of neoplasia imposes individualized assessment, since the safety of supplementation in this scenario has not been established.
The direct transposition of consumer-facing content, especially that disseminated on social media without distinction of species, dose or clinical context, is inadequate and potentially harmful. Evidence-based veterinary practice requires recognizing the limits of available knowledge and communicating them transparently to the owner.
It is concluded that glutamine should occupy an adjuvant position, on an adequate dietary basis in high biological value protein and careful microbiota management, always with individualized assessment. Well-designed veterinary clinical trials, with standardized doses, outcomes and populations, are needed to precisely define the role of this amino acid in small animal practice.
Claudio Amichetti Junior — CRMV 75404 Postgraduate in Animal Nutrition · Postgraduate in Pharmacology · Postgraduate in Medicinal Cannabis
REFERENCES
KIM, Min-Hyun; KIM, Hyeyoung. The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. International Journal of Molecular Sciences, v. 18, n. 5, p. 1051, 2017. DOI: 10.3390/ijms18051051.
RAO, RadhaKrishna; SAMAK, Geetha. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. Current Nutrition & Food Science, v. 8, n. 1, p. 47-54, 2012. DOI: 10.2174/1875044301205010047.
SALAVATI SCHMITZ, Silke. Evidence-based use of biotics in the management of gastrointestinal disorders in dogs and cats. Veterinary Record, 2024. DOI: 10.1002/vetr.4916.
ISIDORI, Marco; CORBEE, Ronald Jan; TRABALZA-MARINUCCI, Massimo. Nonpharmacological Treatment Strategies for the Management of Canine Chronic Inflammatory Enteropathy — A Narrative Review. Veterinary Sciences, v. 9, n. 2, p. 37, 2022. DOI: 10.3390/vetsci9020037.
DRUT, Amandine; MKAOUAR, Héla; KRIAA, Aïcha; MARIAULE, Vincent; AKERMI, Nizar; MÉRIC, Tristan; SÉNÉCAT, Odile; MAGUIN, Emmanuelle; HERNANDEZ, Juan L.; RHIMI, Moez. Gut microbiota in cats with inflammatory bowel disease and low-grade intestinal T-cell lymphoma. Frontiers in Microbiology, v. 15, p. 1346639, 2024. DOI: 10.3389/fmicb.2024.1346639.
MAKIELSKI, Kelly M.; CULLEN, Jonah N.; O'CONNOR, Annette M. Cormier; JERGENS, Albert E. Narrative review of therapies for chronic enteropathies in dogs and cats. Journal of Veterinary Internal Medicine, v. 33, n. 1, p. 11-22, 2019. DOI: 10.1111/jvim.15345.
MELO, Alice Madeira Campos; GHEDIN, Victória; ROMANO, Felipe Saab; DOS SANTOS, Natalia Ribeiro; PELLEGRI, Lara Alice Pagura; ICHIKAWA, Ricardo Shoiti; HUSSNI, Maria Fernanda; PAES, Antônio Carlos; GUIMARÃES-OKAMOTO, Priscylla Tatiana Chalfun; RAHAL, Sheila Canevese; MELCHERT, Alessandra. Oral glutamine supplementation in dogs infected with canine parvovirus type 2. Topics in Companion Animal Medicine, v. 70, p. 101040, 2026. DOI: 10.1016/j.tcam.2025.101040.
MOHR, Albert J.; LEISEWITZ, Andrew L.; JACOBSON, Linda S.; STEINER, Jörg M.; RUAUX, Craig G. Effect of Early Enteral Nutrition on Intestinal Permeability, Intestinal Protein Loss, and Outcome in Dogs with Severe Parvoviral Enteritis. Journal of Veterinary Internal Medicine, v. 17, n. 6, 2003. DOI: 10.1111/j.1939-1676.2003.tb02516.x.
Evaluation of gastrointestinal permeability and mucosal absorptive capacity in dogs with chronic enteropathy. American Journal of Veterinary Research, v. 67, n. 3, p. 479, 2006.
OHNO, Tetsuro; MOCHIKI, Erito; ANDO, Hiroyuki; FUKASAWA, Takaharu; TOYOMASU, Yoshitaka; OGATA, Kyoichi; AIHARA, Ryuusuke; ASAO, Takayuki; KUWANO, Hiroyuki. Glutamine Decreases the Duration of Postoperative Ileus After Abdominal Surgery: An Experimental Study of Conscious Dogs. Digestive Diseases and Sciences, 2008. DOI: 10.1007/s10620-008-0478-5.
KATHRANI, Aarti; YEN, Sandi; HALL, Edward J.; SWANN, Jonathan Richard. The effects of a hydrolyzed protein diet on the plasma, fecal and urine metabolome in cats with chronic enteropathy. Scientific Reports, v. 13, p. 19979, 2023. DOI: 10.1038/s41598-023-47334-y.
ROLPH, Kerry E.; CAVANAUGH, Ryan Patrick. Infectious Causes of Neoplasia in the Domestic Cat. Veterinary Sciences, v. 9, n. 9, p. 467, 2022. DOI: 10.3390/vetsci9090467.
BUCHMANN, Alexandra U.; KERSHAW, Olivia; KEMPF, Volkhard A. J.; GRUBER, Achim D. Does a Feline Leukemia Virus Infection Pave the Way for Bartonella henselae Infection in Cats? Journal of Clinical Microbiology, v. 48, n. 9, 2010. DOI: 10.1128/JCM.00750-10.
MURANAKA, Hayato; AKINSOLA, Rasaq; BILLET, Sandrine; PANDOL, Stephen Jacob; HENDIFAR, Andrew Eugene; BHOWMICK, Neil A.; GONG, Jun. Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention. Cancers, v. 16, n. 5, p. 1057, 2024. DOI: 10.3390/cancers16051057.
FAN, Yuxin; HAN, Xue; LI, Zhimin; HUO, Mingge; GAO, Hongxia; GUAN, Xingang. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment. Frontiers in Pharmacology, v. 15, p. 1345522, 2024. DOI: 10.3389/fphar.2024.1345522.
ABBASI, Fatemeh; HAGHIGHAT LARI, Mohammad Mehdi; KHOSRAVI, Gholamreza Reza; MANSOURI, Elahe; PAYANDEH, Nastaran; MILAJERDI, Alireza. A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults. Amino Acids, 2024. DOI: 10.1007/s00726-024-03420-7.
CRUZAT, Vínicius Fernandes; ROGERO, Marcelo Macedo; KEANE, Kevin Noel; CURI, Rui; NEWSHOLME, Philip. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, v. 10, n. 11, p. 1564, 2018. DOI: 10.3390/nu10111564.
HOLEČEK, Milan. Side Effects of Amino Acid Supplements. Physiological Research, v. 71, n. 1, p. 29-45, 2022. DOI: 10.33549/physiolres.934790.
LÓPEZ MARTÍ, Á.; MONTERO PALMA, C.; LÓPEZ MARTÍ, H.; RANCHAL SÁNCHEZ, A. Efficacy of probiotic, prebiotic, synbiotic and postbiotic supplementation on gastrointestinal health in cats: systematic review and meta-analysis. Journal of Small Animal Practice, v. 66, n. 4, p. 219-232, 2025. DOI: 10.1111/jsap.13822.
WHITTEMORE, Jacqueline C.; STOKES, Jennifer E.; PRICE, Joshua M.; SUCHODOLSKI, Jan S. Effects of a synbiotic on the fecal microbiome and metabolomic profiles of healthy research cats administered clindamycin: a randomized, controlled trial. Gut Microbes, v. 10, n. 4, p. 521-539, 2019. DOI: 10.1080/19490976.2018.1560754.
WANG, Weiwei; MIAO, Chengyi; CHEN, Qianqian; WANG, Longjiao; CHANG, Xiaohan; ZHAO, Lili; MA, Wenqiang; LEI, Shanyu; MA, Mengyao; ZHANG, Yuqiang; CHEN, Shuxing; CHEN, Lishui; WANG, Ran; GE, Shaoyang; XIONG, Wei. Postbiotic supplementation promotes gut barrier integrity and immune balance in cats via microbiota modulation. Frontiers in Microbiology, v. 16, p. 1692845, 2025. DOI: 10.3389/fmicb.2025.1692845.
YANG, Benlu; ZHONG, Shengwei; WANG, Jue; YU, Wanting. Dietary Modulation of the Gut Microbiota in Dogs and Cats and Its Role in Disease Management. Microorganisms, v. 13, n. 12, p. 2669, 2025. DOI: 10.3390/microorganisms13122669.
Глутамин, кишечный барьер и дисбиоз у собак и кошек: от данных исследований на людях к интегративной ветеринарной практике
Claudio Amichetti Junior — CRMV 75404 Специализация в области кормления животных · Специализация в области фармакологии · Специализация в области медицинского каннабиса
РЕЗЮМЕ
Глутамин — наиболее распространённая свободная аминокислота в организме и основной энергетический субстрат для энтероцитов, играющая центральную роль в поддержании целостности кишечного барьера. Интерес к его применению в качестве добавки вырос благодаря распространению информации в сфере здоровья человека, которая часто подаётся в упрощённом виде и без учёта видовых различий. Данный обзор имеет целью критически проанализировать имеющиеся данные о глутамине, кишечном барьере и дисбиозе у собак и кошек, включая контекст вирусной иммуносупрессии у кошек. Были изучены индексируемые базы данных с приоритетом клинических испытаний, систематических обзоров и механистических исследований. У собак рандомизированное клиническое исследование при парвовирусной инфекции продемонстрировало значительное сокращение длительности диареи при пероральном приёме глутамина в дозе 500 мг/кг/сутки, однако с существенными методологическими ограничениями. У кошек клинических испытаний добавок при хронической энтеропатии или дисбиозе не выявлено, а имеющиеся данные являются косвенными и получены в результате метаболомных анализов. У пациентов, инфицированных вирусом лейкемии кошек, повышенный риск новообразований требует дополнительной осторожности, поскольку опухолевые клетки могут проявлять зависимость от глутамина. Сделан вывод, что глутамин следует рассматривать как вспомогательное средство на фоне адекватной диетотерапии и управления микробиотой, но никогда как замену специфической терапии; необходимы хорошо спланированные ветеринарные клинические испытания.
Ключевые слова: глутамин; кишечный барьер; дисбиоз; хроническая энтеропатия; ветеринарная диетология.
1 ВВЕДЕНИЕ
Глутамин — наиболее распространённая свободная аминокислота плазмы, выполняющая функции, выходящие за рамки традиционной классификации как неэссенциальной аминокислоты. В физиологических условиях катаболического стресса его доступность может становиться лимитирующей, что обосновывает определение его как условно эссенциальной аминокислоты. Желудочно-кишечный тракт потребляет значительную часть циркулирующего глутамина, используя его в качестве предпочтительного источника энергии для энтероцитов и предшественника нуклеотидов, глутатиона и других метаболитов, необходимых для обновления эпителия.
В последние десятилетия эти знания закрепились в литературе по клиническому питанию человека и широко распространились в потребительском контенте, включая социальные сети, где глутамин часто представляется как универсальное средство для «улучшения здоровья кишечника и повышения иммунитета». Такая упрощённая подача, хотя и дидактичная, как правило, опускает решающие элементы: изученный вид, использованную дозу, оценённый результат и клинический контекст, в котором тестировалось вмешательство.
Некритический перенос такого контента в ветеринарную практику мелких домашних животных несёт конкретные риски. Собаки и кошки отличаются от людей по физиологии пищеварения, составу микробиоты, метаболизму аминокислот и, прежде всего, по объёму и качеству доступных данных. Кошки, в частности, являются облигатными хищниками с хорошо документированными метаболическими особенностями, включая более высокие эндогенные потери азота и повышенные потребности в специфических аминокислотах.
Цель данной работы — критически обобщить данные о глутамине, целостности кишечного барьера и дисбиозе у собак и кошек, с особым вниманием к контексту вирусной иммуносупрессии у кошек, и предложить интегрированный клинический подход к рациональному применению этой аминокислоты в ветеринарной практике.
2 ОСНОВЫ: ГЛУТАМИН И ЭНТЕРОЦИТ
Глутамин выполняет множественные функции в слизистой оболочке кишечника. Он является первичным энергетическим субстратом для энтероцитов, участвует в синтезе нуклеотидов и глутатиона, а также регулирует экспрессию белков плотных контактов, включая окклюдин, клаудины и белок замыкающей зоны ZO-1. Эти контакты являются главным фактором парацеллюлярной проницаемости и, следовательно, функциональной полноценности эпителиального барьера.
Помимо структурного эффекта, глутамин модулирует сигнальные пути воспаления, подавляя активацию ядерного фактора каппа B (NF-kB), и защищает эпителиальные клетки от апоптоза и окислительного стресса. В экспериментальных моделях истощение глутамина связано с повышением проницаемости кишечника, атрофией ворсинок и усилением бактериальной транслокации.
Kim и Kim в обзоре, опубликованном в International Journal of Molecular Sciences, обобщают этот комплекс механизмов и отмечают, что добавление глутамина изучалось в условиях тяжёлого метаболического стресса, включая травму, сепсис и воспалительные заболевания кишечника. Rao в статье, специально посвящённой защите плотных контактов, описывает, что защитный эффект глутамина на слизистый барьер напрямую связан с сохранением целостности этих контактов.
Однако важно различать механистическую обоснованность и доказанную клиническую эффективность. Описанные механизмы надёжны и воспроизводимы в экспериментальных моделях, но перенос в клинические результаты у ветеринарных видов требует специальных исследований с адекватно определёнными дозами, путями введения и популяциями.
3 ДИСБИОЗ: ПОНЯТИЕ И ЗНАЧЕНИЕ У МЕЛКИХ ДОМАШНИХ ЖИВОТНЫХ
Дисбиоз обозначает нарушение состава и функции кишечной микробиоты. Речь идёт не только об изменении относительного обилия определённых таксонов, но об изменении метаболических профилей микроорганизмов с последствиями для продукции короткоцепочечных жирных кислот, метаболизма жёлчных кислот и локальной иммунной модуляции.
У собак и кошек дисбиоз связан с хронической диареей и хронической энтеропатией — состояниями с гетерогенной этиологией и сложной диагностикой. Связь между дисбиозом и воспалением слизистой является двунаправленной: воспаление изменяет среду просвета и микробный состав, а изменённая микробиота поддерживает воспалительный ответ и нарушает эпителиальный барьер.
Кишечный барьер следует понимать как интегрированную функциональную структуру, состоящую из слизи, плотных контактов, эпителиальных клеток и лимфоидной ткани, ассоциированной с кишечником (GALT). Нарушение любого из этих компонентов повышает проницаемость для токсинов и патогенов с последующей системной воспалительной активацией.
Salavati Schmitz в обзоре, опубликованном в Veterinary Record, анализирует применение пребиотиков, пробиотиков и постбиотиков при нарушениях желудочно-кишечного тракта у собак и кошек, подчёркивая потенциал снижения использования антимикробных препаратов, но также необходимость тщательной интерпретации имеющихся данных. Isidori, Corbee и Trabalza-Marinucci в обзоре нефармакологических стратегий при хронической воспалительной энтеропатии собак определяют целостность кишечного барьера и воспаление слизистой как центральные терапевтические мишени наряду с модуляцией микробиоты.
В контексте кошек Drut и соавторы обобщают данные о кишечной микробиоте кошек с воспалительным заболеванием кишечника и низкозлокачественной кишечной лимфомой — состояниями, имеющими общие механизмы с воспалительным заболеванием кишечника человека, в которых микробный дисбаланс, по-видимому, играет значимую роль. Makielski и соавторы в повествовательном обзоре методов лечения хронических энтеропатий показывают, что доказательная база существенно шире у собак, чем у кошек, причём терапевтические желудочно-кишечные диеты и глюкокортикоиды являются вмешательствами с наилучшей поддержкой у кошек.
4 ДАННЫЕ У СОБАК
Доказательная база у собак, хотя и остаётся ограниченной, является наиболее последовательной в ветеринарии. Наиболее значимое доступное исследование — рандомизированное клиническое испытание, проведённое Melo и соавторами в Университете штата Сан-Паулу, кампус Ботукату, опубликованное в Topics in Companion Animal Medicine.
Авторы оценили 20 собак с парвовирусной инфекцией 2-го типа, случайным образом распределённых на две группы. Группа лечения получала глутамин в дозе 500 мг/кг/сутки перорально в сочетании со свободным кормлением, тогда как контрольная группа получала плацебо в тех же условиях кормления. Оцениваемые результаты включали длительность диареи, оценку кала, время до клинического улучшения, продолжительность госпитализации и смертность.
Результаты показали значительное сокращение длительности диареи в группе глутамина — в среднем 2,4 дня против 4,9 дня в контрольной группе. Оценка кала также была лучше в группе лечения — медиана 5 против 6,5 в контроле. В группе глутамина не было летальных исходов, тогда как в контрольной группе зарегистрирована смертность 10%, что соответствует одному животному. Значимых различий по времени до начала самостоятельного питания, времени до клинического улучшения или продолжительности госпитализации не наблюдалось.
Сами авторы признают важные ограничения. Выборка мала — по десять животных в группе. Наблюдалась значительная разница в возрасте между группами: группа глутамина состояла из более молодых животных, в среднем 3,5 месяца против 6,3 месяца в контроле. Кроме того, уровни альбумина были ниже в группе лечения при первичной оценке, что может отражать различия в тяжести состояния или нутритивном статусе при поступлении. Эти факторы ограничивают причинную интерпретацию результатов, хотя наблюдаемый клинический исход значим и оправдывает дальнейшие исследования.
Другие исследования способствуют патофизиологическому обоснованию. Mohr и соавторы продемонстрировали у собак с тяжёлым парвовирусным энтеритом, что раннее энтеральное питание влияет на проницаемость кишечника, кишечные потери белка и клинический исход, что подтверждает важность целостности барьера для выздоровления. Исследование, опубликованное в American Journal of Veterinary Research, оценило желудочно-кишечную проницаемость и абсорбционную способность слизистой у собак с хронической энтеропатией, подтвердив, что дисфункция барьера измерима в этой популяции. Ohno и соавторы в экспериментальной модели на бодрствующих собаках наблюдали, что глутамин сокращает длительность послеоперационного илеуса после абдоминальной хирургии, что указывает на влияние на моторику и функциональное восстановление кишечника.
В совокупности эти исследования подтверждают обоснованность и сигнал о пользе, но не позволяют экстраполировать на стандартизированные протоколы при хронической энтеропатии собак — контексте, в котором глутамин не оценивался в рандомизированных испытаниях.
5 ДАННЫЕ У КОШЕК И КОНТЕКСТ FeLV+
Ситуация у кошек существенно иная. Рандомизированных клинических испытаний, оценивающих добавление глутамина у кошек с хронической энтеропатией, дисбиозом или любым другим желудочно-кишечным состоянием, не выявлено. Большая часть знаний, применяемых к этому виду, экстраполирована из других популяций, что накладывает очевидные ограничения.
Имеющиеся данные являются косвенными. Kathrani и соавторы в метаболомном исследовании, опубликованном в Scientific Reports, оценили кошек с хронической энтеропатией, получавших диету с гидролизованным белком. В когорте Бристоля плазменный глутамин при поступлении вошёл в число метаболитов, предсказывающих исход, наряду с бетаином, глицерином и аланином. Этот результат не воспроизвёлся в когорте Королевского ветеринарного колледжа, и сами авторы объясняют расхождение различиями в тяжести, гетерогенностью заболевания и малым размером выборки. Данные указывают на ценность глутамина как метаболического маркера, а не как установленного терапевтического вмешательства.
Что касается вируса лейкемии кошек, это онкогенный ретровирус, связанный с иммуносупрессией, анемией и лимфомой. Rolph и Cavanaugh в обзоре инфекционных причин новообразований у кошек относят FeLV к числу первых агентов, признанных онкогенными у этого вида. Вирусная иммуносупрессия нарушает кишечную слизистую и GALT, способствуя дисбиозу, бактериальной транслокации и оппортунистическим инфекциям. Buchmann и соавторы продемонстрировали значимую связь между инфекцией FeLV и повышенной восприимчивостью кошек к Bartonella henselae, что подтверждает влияние вирусной иммуносупрессии на мукозальную иммунную компетентность.
В этом сценарии добавление глутамина требует особенно тщательного анализа соотношения риска и пользы. Опухолевые клетки могут проявлять зависимость от глутамина — феномен, описанный в онкологической литературе как «глутаминовая зависимость» (glutamine addiction). Muranaka и соавторы в обзоре, опубликованном в Cancers, обсуждают тонкий баланс между добавлением, поддерживающим целостность кишечника и иммунную функцию, и теоретической возможностью стимулирования опухолегенеза. Fan и соавторы в обзоре метаболизма глутамина как терапевтической мишени описывают роль этой аминокислоты как источника азота и углерода для пролиферирующих опухолевых клеток.
Важно признать, что эти данные получены на моделях человека и экспериментальных моделях. Ветеринарных данных, устанавливающих безопасность добавления глутамина у FeLV-положительных кошек с высоким риском лимфомы, не существует. Поэтому решение должно быть индивидуализированным, с учётом клинической стадии, наличия новообразования, нутритивного статуса и динамического наблюдения.
6 БЕЗОПАСНОСТЬ, ДОЗИРОВКА И МЕТОДОЛОГИЧЕСКИЕ ОГРАНИЧЕНИЯ
Единственная доза, задокументированная в рандомизированном ветеринарном клиническом испытании, — 500 мг/кг/сутки, применённая в исследовании парвовирусной инфекции собак. Стандартизации дозы при хронической энтеропатии у собак, как и при любом состоянии у кошек, не существует. Биодоступность, путь введения, кратность приёма и длительность лечения остаются неопределёнными в ветеринарии.
Данные исследований на людях дают важный контрапункт энтузиазму. Abbasi и соавторы в систематическом обзоре с метаанализом, опубликованном в Amino Acids, проанализировали десять клинических испытаний с 352 участниками и пришли к выводу, что добавление глутамина в целом не изменило проницаемость кишечника значимо. Эффект становился значимым только при дозах выше 30 г/сутки и в течение периодов менее двух недель. Этот результат релятивизирует ожидание универсальной пользы и подчёркивает необходимость научного скептицизма в отношении общих рекомендаций.
Cruzat и соавторы в обширном обзоре метаболизма и иммунной функции глутамина подчёркивают, что, хотя иммунологические эффекты добавления установлены, остаются значимые вопросы относительно результатов in vivo в различных катаболических ситуациях. Holeček, рассматривая побочные эффекты добавок аминокислот, предупреждает, что повышенное потребление глутамина не лишено риска, с потенциальным влиянием на функцию почек, продукцию аммиака и конкуренцию с другими аминокислотами за мембранные транспортеры.
С практической точки зрения препаративная форма также накладывает ограничения: нестабильность глутамина в растворе, вариабельная поедаемость и стоимость длительного применения — факторы, влияющие на приверженность владельца и осуществимость протокола.
7 КЛИНИЧЕСКАЯ ИНТЕГРАЦИЯ: МЕСТО ГЛУТАМИНА
Глутамин следует понимать как вспомогательное средство, но никогда как замену вмешательств с более прочной доказательной базой. Терапевтическая иерархия при хронической энтеропатии и дисбиозе остаётся сосредоточенной на четырёх опорах: адекватная терапевтическая диета с использованием гидролизованного белка или элиминационной диеты по показаниям; управление биотиками под профессиональным руководством, включая пребиотики, пробиотики, постбиотики и, в отдельных случаях, трансплантацию фекальной микробиоты; контроль воспаления; и специфическое этиологическое лечение.
Систематический обзор с метаанализом López Martí и соавторов, опубликованный в Journal of Small Animal Practice, оценил эффективность биотиков у кошек и пришёл к выводу, что достоверность доказательств низкая или очень низкая, с благоприятными результатами в части испытаний пробиотиков в отношении консистенции кала, но без надёжной поддержки для безоговорочной рекомендации. Whittemore и соавторы в рандомизированном контролируемом исследовании показали, что введение синбиотика модулирует микробиом и метаболом кала у кошек, получавших клиндамицин, с изменениями в путях короткоцепочечных жирных кислот, жёлчных кислот и полиаминов. Wang и соавторы наблюдали, что добавление постбиотика улучшило целостность кишечного барьера у кошек со снижением маркеров проницаемости, таких как диаминоксидаза и липополисахарид, а также повышением иммуноглобулина G и противовоспалительных цитокинов.
С точки зрения интегративной ветеринарной медицины глутамин дополняет другие информационные градиенты, сходящиеся к восстановлению гомеостаза. Фармакология эндоканнабиноидной системы предлагает ресурсы для контроля хронического воспаления и иммуномодуляции; регенеративное клиническое питание, включая изучение пептидов, направлено на поддержку процессов восстановления тканей; а модуляция микробиоты составляет основу, на которой опираются остальные вмешательства. Сочетание каннабиноидов и глутамина имеет биологическое обоснование, но не имеет специфических исследований взаимодействия, что следует учитывать при назначении.
8 ЗАКЛЮЧИТЕЛЬНЫЕ ЗАМЕЧАНИЯ
Глутамин обладает прочной биологической обоснованностью и многообещающими клиническими данными у собак, особенно в контексте парвовирусной инфекции, где рандомизированное испытание продемонстрировало сокращение длительности диареи и улучшение оценки кала. Однако эти результаты получены на малой выборке и имеют методологические ограничения, препятствующие немедленному обобщению.
При хроническом дисбиозе доказательства остаются слабыми у обоих видов. У кошек они практически отсутствуют и ограничиваются метаболомными данными, которые определяют глутамин как маркер, а не как установленную терапию. У пациентов, инфицированных вирусом лейкемии кошек, повышенный риск новообразований требует индивидуализированной оценки, поскольку безопасность добавления в этом сценарии не установлена.
Прямой перенос потребительского контента, особенно распространяемого в социальных сетях без разграничения вида, дозы или клинического контекста, неадекватен и потенциально вреден. Ветеринарная практика, основанная на доказательствах, требует признания границ имеющихся знаний и прозрачного информирования о них владельца.
Сделан вывод, что глутамин должен занимать вспомогательную позицию на фоне адекватной диеты с высоким биологическим качеством белка и тщательного управления микробиотой, всегда с индивидуализированной оценкой. Необходимы хорошо спланированные ветеринарные клинические испытания со стандартизированными дозами, результатами и популяциями, чтобы точно определить роль этой аминокислоты в практике мелких домашних животных.
Claudio Amichetti Junior — CRMV 75404 Специализация в области кормления животных · Специализация в области фармакологии · Специализация в области медицинского каннабиса
ЛИТЕРАТУРА
KIM, Min-Hyun; KIM, Hyeyoung. The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. International Journal of Molecular Sciences, v. 18, n. 5, p. 1051, 2017. DOI: 10.3390/ijms18051051.
RAO, RadhaKrishna; SAMAK, Geetha. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. Current Nutrition & Food Science, v. 8, n. 1, p. 47-54, 2012. DOI: 10.2174/1875044301205010047.
SALAVATI SCHMITZ, Silke. Evidence-based use of biotics in the management of gastrointestinal disorders in dogs and cats. Veterinary Record, 2024. DOI: 10.1002/vetr.4916.
ISIDORI, Marco; CORBEE, Ronald Jan; TRABALZA-MARINUCCI, Massimo. Nonpharmacological Treatment Strategies for the Management of Canine Chronic Inflammatory Enteropathy — A Narrative Review. Veterinary Sciences, v. 9, n. 2, p. 37, 2022. DOI: 10.3390/vetsci9020037.
DRUT, Amandine; MKAOUAR, Héla; KRIAA, Aïcha; MARIAULE, Vincent; AKERMI, Nizar; MÉRIC, Tristan; SÉNÉCAT, Odile; MAGUIN, Emmanuelle; HERNANDEZ, Juan L.; RHIMI, Moez. Gut microbiota in cats with inflammatory bowel disease and low-grade intestinal T-cell lymphoma. Frontiers in Microbiology, v. 15, p. 1346639, 2024. DOI: 10.3389/fmicb.2024.1346639.
MAKIELSKI, Kelly M.; CULLEN, Jonah N.; O'CONNOR, Annette M. Cormier; JERGENS, Albert E. Narrative review of therapies for chronic enteropathies in dogs and cats. Journal of Veterinary Internal Medicine, v. 33, n. 1, p. 11-22, 2019. DOI: 10.1111/jvim.15345.
MELO, Alice Madeira Campos; GHEDIN, Victória; ROMANO, Felipe Saab; DOS SANTOS, Natalia Ribeiro; PELLEGRI, Lara Alice Pagura; ICHIKAWA, Ricardo Shoiti; HUSSNI, Maria Fernanda; PAES, Antônio Carlos; GUIMARÃES-OKAMOTO, Priscylla Tatiana Chalfun; RAHAL, Sheila Canevese; MELCHERT, Alessandra. Oral glutamine supplementation in dogs infected with canine parvovirus type 2. Topics in Companion Animal Medicine, v. 70, p. 101040, 2026. DOI: 10.1016/j.tcam.2025.101040.
MOHR, Albert J.; LEISEWITZ, Andrew L.; JACOBSON, Linda S.; STEINER, Jörg M.; RUAUX, Craig G. Effect of Early Enteral Nutrition on Intestinal Permeability, Intestinal Protein Loss, and Outcome in Dogs with Severe Parvoviral Enteritis. Journal of Veterinary Internal Medicine, v. 17, n. 6, 2003. DOI: 10.1111/j.1939-1676.2003.tb02516.x.
Evaluation of gastrointestinal permeability and mucosal absorptive capacity in dogs with chronic enteropathy. American Journal of Veterinary Research, v. 67, n. 3, p. 479, 2006.
OHNO, Tetsuro; MOCHIKI, Erito; ANDO, Hiroyuki; FUKASAWA, Takaharu; TOYOMASU, Yoshitaka; OGATA, Kyoichi; AIHARA, Ryuusuke; ASAO, Takayuki; KUWANO, Hiroyuki. Glutamine Decreases the Duration of Postoperative Ileus After Abdominal Surgery: An Experimental Study of Conscious Dogs. Digestive Diseases and Sciences, 2008. DOI: 10.1007/s10620-008-0478-5.
KATHRANI, Aarti; YEN, Sandi; HALL, Edward J.; SWANN, Jonathan Richard. The effects of a hydrolyzed protein diet on the plasma, fecal and urine metabolome in cats with chronic enteropathy. Scientific Reports, v. 13, p. 19979, 2023. DOI: 10.1038/s41598-023-47334-y.
ROLPH, Kerry E.; CAVANAUGH, Ryan Patrick. Infectious Causes of Neoplasia in the Domestic Cat. Veterinary Sciences, v. 9, n. 9, p. 467, 2022. DOI: 10.3390/vetsci9090467.
BUCHMANN, Alexandra U.; KERSHAW, Olivia; KEMPF, Volkhard A. J.; GRUBER, Achim D. Does a Feline Leukemia Virus Infection Pave the Way for Bartonella henselae Infection in Cats? Journal of Clinical Microbiology, v. 48, n. 9, 2010. DOI: 10.1128/JCM.00750-10.
MURANAKA, Hayato; AKINSOLA, Rasaq; BILLET, Sandrine; PANDOL, Stephen Jacob; HENDIFAR, Andrew Eugene; BHOWMICK, Neil A.; GONG, Jun. Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention. Cancers, v. 16, n. 5, p. 1057, 2024. DOI: 10.3390/cancers16051057.
FAN, Yuxin; HAN, Xue; LI, Zhimin; HUO, Mingge; GAO, Hongxia; GUAN, Xingang. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment. Frontiers in Pharmacology, v. 15, p. 1345522, 2024. DOI: 10.3389/fphar.2024.1345522.
ABBASI, Fatemeh; HAGHIGHAT LARI, Mohammad Mehdi; KHOSRAVI, Gholamreza Reza; MANSOURI, Elahe; PAYANDEH, Nastaran; MILAJERDI, Alireza. A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults. Amino Acids, 2024. DOI: 10.1007/s00726-024-03420-7.
CRUZAT, Vínicius Fernandes; ROGERO, Marcelo Macedo; KEANE, Kevin Noel; CURI, Rui; NEWSHOLME, Philip. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, v. 10, n. 11, p. 1564, 2018. DOI: 10.3390/nu10111564.
HOLEČEK, Milan. Side Effects of Amino Acid Supplements. Physiological Research, v. 71, n. 1, p. 29-45, 2022. DOI: 10.33549/physiolres.934790.
LÓPEZ MARTÍ, Á.; MONTERO PALMA, C.; LÓPEZ MARTÍ, H.; RANCHAL SÁNCHEZ, A. Efficacy of probiotic, prebiotic, synbiotic and postbiotic supplementation on gastrointestinal health in cats: systematic review and meta-analysis. Journal of Small Animal Practice, v. 66, n. 4, p. 219-232, 2025. DOI: 10.1111/jsap.13822.
WHITTEMORE, Jacqueline C.; STOKES, Jennifer E.; PRICE, Joshua M.; SUCHODOLSKI, Jan S. Effects of a synbiotic on the fecal microbiome and metabolomic profiles of healthy research cats administered clindamycin: a randomized, controlled trial. Gut Microbes, v. 10, n. 4, p. 521-539, 2019. DOI: 10.1080/19490976.2018.1560754.
WANG, Weiwei; MIAO, Chengyi; CHEN, Qianqian; WANG, Longjiao; CHANG, Xiaohan; ZHAO, Lili; MA, Wenqiang; LEI, Shanyu; MA, Mengyao; ZHANG, Yuqiang; CHEN, Shuxing; CHEN, Lishui; WANG, Ran; GE, Shaoyang; XIONG, Wei. Postbiotic supplementation promotes gut barrier integrity and immune balance in cats via microbiota modulation. Frontiers in Microbiology, v. 16, p. 1692845, 2025. DOI: 10.3389/fmicb.2025.1692845.
YANG, Benlu; ZHONG, Shengwei; WANG, Jue; YU, Wanting. Dietary Modulation of the Gut Microbiota in Dogs and Cats and Its Role in Disease Management. Microorganisms, v. 13, n. 12, p. 2669, 2025. DOI: 10.3390/microorganisms13122669.
ग्लूटामाइन, आंतों की बाधा और कुत्तों तथा बिल्लियों में डिस्बायोसिस: मानवीय साक्ष्यों से एकीकृत पशु चिकित्सा अभ्यास तक
Claudio Amichetti Junior — CRMV 75404 पशु पोषण में स्नातकोत्तर · औषध विज्ञान में स्नातकोत्तर · चिकित्सीय भांग में स्नातकोत्तर
सारांश
ग्लूटामाइन शरीर में सबसे प्रचुर मात्रा में उपलब्ध मुक्त अमीनो अम्ल है और एंटेरोसाइट्स के लिए मुख्य ऊर्जा स्रोत है, जो आंतों की बाधा की अखंडता बनाए रखने में केंद्रीय भूमिका निभाता है। इसके पूरक के प्रति रुचि मानव स्वास्थ्य संचार से बढ़ी है, जिसे अक्सर सरलीकृत रूप में और प्रजातिगत भेद के बिना प्रस्तुत किया जाता है। यह वर्णनात्मक समीक्षा कुत्तों और बिल्लियों में ग्लूटामाइन, आंतों की बाधा और डिस्बायोसिस पर उपलब्ध साक्ष्यों का आलोचनात्मक विश्लेषण करने का लक्ष्य रखती है, जिसमें बिल्लियों में वायरल इम्यूनोसप्रेशन का संदर्भ भी शामिल है। अनुक्रमित डेटाबेस से परामर्श किया गया, जिसमें नैदानिक परीक्षणों, व्यवस्थित समीक्षाओं और तंत्र-आधारित अध्ययनों को प्राथमिकता दी गई। कुत्तों में, कैनाइन पार्वोवायरस पर एक यादृच्छिक नैदानिक परीक्षण ने 500 मिलीग्राम/किग्रा/दिन मौखिक ग्लूटामाइन के साथ दस्त की अवधि में महत्वपूर्ण कमी दर्शाई, हालांकि इसमें महत्वपूर्ण पद्धतिगत सीमाएं थीं। बिल्लियों में, पुरानी एंटेरोपैथी या डिस्बायोसिस में पूरक के कोई नैदानिक परीक्षण नहीं मिले, और उपलब्ध साक्ष्य अप्रत्यक्ष हैं, जो मेटाबोलोमिक विश्लेषणों से प्राप्त हैं। फेलाइन ल्यूकेमिया वायरस से संक्रमित रोगियों में, नियोप्लासिया का बढ़ा हुआ जोखिम अतिरिक्त सावधानी की मांग करता है, क्योंकि ट्यूमर कोशिकाओं में ग्लूटामाइन निर्भरता हो सकती है। निष्कर्ष यह है कि ग्लूटामाइन को पर्याप्त आहार आधार और माइक्रोबायोटा प्रबंधन पर एक सहायक उपाय के रूप में स्थापित किया जाना चाहिए, कभी भी विशिष्ट चिकित्सा का विकल्प नहीं, और अच्छी तरह से डिज़ाइन किए गए पशु चिकित्सा नैदानिक परीक्षणों की आवश्यकता है।
मुख्य शब्द: ग्लूटामाइन; आंतों की बाधा; डिस्बायोसिस; पुरानी एंटेरोपैथी; पशु पोषण।
1 परिचय
ग्लूटामाइन प्लाज्मा में सबसे प्रचुर मात्रा में उपलब्ध मुक्त अमीनो अम्ल है और ऐसे कार्य करता है जो पारंपरिक रूप से गैर-आवश्यक अमीनो अम्ल के रूप में इसके वर्गीकरण से परे हैं। अपचयी तनाव की शारीरिक स्थितियों में, इसकी उपलब्धता सीमित हो सकती है, जो इसे सशर्त आवश्यक अमीनो अम्ल के रूप में नामित करने को उचित ठहराता है। जठरांत्र पथ परिसंचारी ग्लूटामाइन का महत्वपूर्ण हिस्सा उपभोग करता है, इसे एंटेरोसाइट्स के लिए प्राथमिक ऊर्जा स्रोत और एपिथेलियल नवीकरण के लिए आवश्यक न्यूक्लियोटाइड्स, ग्लूटाथियोन और अन्य मेटाबोलाइट्स के पूर्ववर्ती के रूप में उपयोग करता है।
हाल के दशकों में, यह ज्ञान नैदानिक मानव पोषण साहित्य में समेकित हुआ है और उपभोक्ता-उन्मुख सामग्री में व्यापक रूप से प्रसारित हुआ है, जिसमें सोशल मीडिया भी शामिल है, जहां ग्लूटामाइन को अक्सर "आंतों का स्वास्थ्य सुधारने और प्रतिरक्षा बढ़ाने" के लिए एक सामान्य संसाधन के रूप में प्रस्तुत किया जाता है। यह सरलीकृत संचार, हालांकि शैक्षिक है, निर्णायक तत्वों को छिपा देता है: अध्ययन की गई प्रजाति, प्रयुक्त खुराक, मूल्यांकित परिणाम और वह नैदानिक संदर्भ जिसमें हस्तक्षेप का परीक्षण किया गया था।
इस सामग्री का छोटे पशु पशु चिकित्सा में अविवेकपूर्ण स्थानांतरण ठोस जोखिम लेकर आता है। कुत्ते और बिल्लियां पाचन शरीर क्रिया विज्ञान, माइक्रोबायोटा संरचना, अमीनो अम्ल चयापचय और, सबसे महत्वपूर्ण, उपलब्ध साक्ष्यों की मात्रा और गुणवत्ता में मनुष्यों से भिन्न हैं। विशेष रूप से बिल्लियां अनिवार्य मांसाहारी हैं जिनमें अच्छी तरह से प्रलेखित चयापचय विशेषताएं हैं, जिनमें अधिक अंतर्जात नाइट्रोजन हानि और विशिष्ट अमीनो अम्लों की उच्च आवश्यकताएं शामिल हैं।
यह कार्य कुत्तों और बिल्लियों में ग्लूटामाइन, आंतों की बाधा की अखंडता और डिस्बायोसिस पर साक्ष्यों की आलोचनात्मक समीक्षा करने का लक्ष्य रखता है, बिल्लियों में वायरल इम्यूनोसप्रेशन के संदर्भ पर विशेष ध्यान देते हुए, और पशु चिकित्सा अभ्यास में इस अमीनो अम्ल के तर्कसंगत उपयोग के लिए एक एकीकृत नैदानिक तर्क प्रस्तावित करता है।
2 मूल सिद्धांत: ग्लूटामाइन और एंटेरोसाइट
ग्लूटामाइन आंतों की श्लेष्मा में कई कार्य करता है। यह एंटेरोसाइट्स के लिए प्राथमिक ऊर्जा स्रोत है, न्यूक्लियोटाइड्स और ग्लूटाथियोन के संश्लेषण में भाग लेता है, और टाइट जंक्शन प्रोटीन की अभिव्यक्ति को नियंत्रित करता है, जिसमें ऑक्लुडिन, क्लॉडिन और ज़ोनुला ऑक्लुडेंस प्रोटीन ZO-1 शामिल हैं। ये जंक्शन पैरासेलुलर पारगम्यता के मुख्य निर्धारक हैं और इसलिए एपिथेलियल बाधा की क्षमता के भी।
संरचनात्मक प्रभाव से परे, ग्लूटामाइन सूजन संकेतन मार्गों को नियंत्रित करता है, परमाणु कारक कापा B (NF-kB) की सक्रियता को दबाता है, और एपिथेलियल कोशिकाओं को एपोप्टोसिस और ऑक्सीडेटिव तनाव से बचाता है। प्रायोगिक मॉडलों में, ग्लूटामाइन की कमी आंतों की बढ़ी हुई पारगम्यता, विलस एट्रोफी और अधिक जीवाणु ट्रांसलोकेशन से जुड़ी है।
Kim और Kim, International Journal of Molecular Sciences में प्रकाशित समीक्षा में, इस तंत्र समूह को संश्लेषित करते हैं और बताते हैं कि ग्लूटामाइन पूरकता का अध्ययन गंभीर चयापचय तनाव के संदर्भों में किया गया है, जिसमें आघात, सेप्सिस और सूजन आंत्र रोग शामिल हैं। Rao, विशेष रूप से टाइट जंक्शन सुरक्षा को समर्पित लेख में, वर्णन करते हैं कि श्लेष्मा बाधा पर ग्लूटामाइन का सुरक्षात्मक प्रभाव सीधे इन जंक्शनों की अखंडता के संरक्षण से संबंधित है।
हालांकि, तंत्र की प्रशंसनीयता और सिद्ध नैदानिक प्रभावशीलता के बीच अंतर करना महत्वपूर्ण है। वर्णित तंत्र प्रायोगिक मॉडलों में मजबूत और प्रतिलिपि प्रस्तुत करने योग्य हैं, लेकिन पशु चिकित्सा प्रजातियों में नैदानिक परिणामों में अनुवाद के लिए पर्याप्त रूप से परिभाषित खुराक, प्रशासन मार्ग और आबादी वाले विशिष्ट अध्ययनों की आवश्यकता होती है।
3 डिस्बायोसिस: अवधारणा और छोटे पशुओं में प्रासंगिकता
डिस्बायोसिस आंतों के माइक्रोबायोटा की संरचना और कार्य के असंतुलन को दर्शाता है। यह केवल कुछ टैक्सा की सापेक्ष बहुतायत में परिवर्तन नहीं है, बल्कि माइक्रोबियल चयापचय प्रोफाइल का संशोधन है, जिसका शॉर्ट-चेन फैटी एसिड उत्पादन, पित्त अम्ल चयापचय और स्थानीय प्रतिरक्षा मॉडुलन पर परिणाम होता है।
कुत्तों और बिल्लियों में, डिस्बायोसिस पुरानी दस्त और पुरानी एंटेरोपैथी से जुड़ा है, जो विषम एटियोलॉजी और चुनौतीपूर्ण निदान वाली स्थितियां हैं। डिस्बायोसिस और श्लेष्मा सूजन के बीच संबंध द्विदिशात्मक है: सूजन लुमेन वातावरण और माइक्रोबियल संरचना को बदलती है, जबकि परिवर्तित माइक्रोबायोटा सूजन प्रतिक्रिया को बनाए रखता है और एपिथेलियल बाधा से समझौता करता है।
आंतों की बाधा को एक एकीकृत कार्यात्मक संरचना के रूप में समझा जाना चाहिए, जो श्लेष्म, टाइट जंक्शन, एपिथेलियल कोशिकाओं और आंत से जुड़े लसीका ऊतक (GALT) से बनी है। इनमें से किसी भी घटक की विफलता विषाक्त पदार्थों और रोगजनकों के प्रति पारगम्यता बढ़ाती है, जिसके बाद द्वितीयक प्रणालीगत सूजन सक्रियता होती है।
Salavati Schmitz, Veterinary Record में प्रकाशित समीक्षा में, कुत्तों और बिल्लियों में जठरांत्र विकारों के प्रबंधन में प्रीबायोटिक्स, प्रोबायोटिक्स और पोस्टबायोटिक्स के उपयोग का विश्लेषण करते हैं, रोगाणुरोधी उपयोग को कम करने की क्षमता पर प्रकाश डालते हैं, लेकिन उपलब्ध साक्ष्यों की सावधानीपूर्वक व्याख्या की आवश्यकता पर भी। Isidori, Corbee और Trabalza-Marinucci, कैनाइन पुरानी सूजन एंटेरोपैथी में गैर-औषधीय रणनीतियों पर समीक्षा में, आंतों की बाधा की अखंडता और श्लेष्मा सूजन को माइक्रोबायोटा मॉडुलन के साथ केंद्रीय चिकित्सीय लक्ष्यों के रूप में स्थापित करते हैं।
बिल्ली के संदर्भ में, Drut और सहयोगी सूजन आंत्र रोग और निम्न-श्रेणी आंतों के लिम्फोमा वाली बिल्लियों के आंतों के माइक्रोबायोटा की समीक्षा करते हैं, ऐसी स्थितियां जो मानव सूजन आंत्र रोग के साथ तंत्र साझा करती हैं और जिनमें माइक्रोबियल असंतुलन महत्वपूर्ण भूमिका निभाता प्रतीत होता है। Makielski और सहयोगी, पुरानी एंटेरोपैथी के उपचारों पर वर्णनात्मक समीक्षा में, प्रदर्शित करते हैं कि साक्ष्य आधार कुत्तों में बिल्लियों की तुलना में काफी बड़ा है, चिकित्सीय जठरांत्र आहार और ग्लूकोकार्टिकोइड्स बिल्लियों में सबसे अच्छा समर्थन वाले हस्तक्षेप हैं।
4 कुत्तों में साक्ष्य
कैनाइन साक्ष्य आधार, हालांकि अभी भी सीमित है, पशु चिकित्सा में सबसे सुसंगत है। सबसे प्रासंगिक उपलब्ध अध्ययन Melo और सहयोगियों द्वारा साओ पाउलो स्टेट यूनिवर्सिटी, बोटुकाटू परिसर में आयोजित यादृच्छिक नैदानिक परीक्षण है, जो Topics in Companion Animal Medicine में प्रकाशित हुआ।
लेखकों ने कैनाइन पार्वोवायरस प्रकार 2 वाले 20 कुत्तों का मूल्यांकन किया, जिन्हें यादृच्छिक रूप से दो समूहों में विभाजित किया गया। उपचार समूह को 500 मिलीग्राम/किग्रा/दिन ग्लूटामाइन मौखिक रूप से, एड लिबिटम भोजन के साथ प्राप्त हुआ, जबकि नियंत्रण समूह को समान भोजन स्थितियों में प्लेसीबो प्राप्त हुआ। परिणामों में दस्त की अवधि, मल स्कोर, नैदानिक सुधार का समय, अस्पताल में भर्ती की अवधि और मृत्यु दर शामिल थे।
परिणामों ने ग्लूटामाइन समूह में दस्त की अवधि में महत्वपूर्ण कमी दर्शाई, औसतन 2.4 दिन, नियंत्रण समूह में 4.9 दिन के मुकाबले। उपचार समूह में मल स्कोर भी बेहतर था, मध्यिका 5, नियंत्रण में 6.5 के मुकाबले। ग्लूटामाइन समूह में कोई मृत्यु नहीं हुई, जबकि नियंत्रण समूह में 10% मृत्यु दर दर्ज की गई, जो एक जानवर के बराबर है। स्वतः भोजन शुरू होने के समय, नैदानिक सुधार के समय या अस्पताल में भर्ती की अवधि में कोई महत्वपूर्ण अंतर नहीं देखा गया।
लेखक स्वयं महत्वपूर्ण सीमाओं को स्वीकार करते हैं। नमूना छोटा है, प्रति समूह दस जानवर। समूहों के बीच उम्र में महत्वपूर्ण अंतर था, ग्लूटामाइन समूह में युवा जानवर थे, औसतन 3.5 महीने, नियंत्रण में 6.3 महीने के मुकाबले। इसके अलावा, प्रारंभिक मूल्यांकन में उपचार समूह में एल्ब्यूमिन स्तर कम थे, जो प्रवेश पर गंभीरता या पोषण स्थिति में अंतर को दर्शा सकता है। ये कारक निष्कर्षों की कारणात्मक व्याख्या को सीमित करते हैं, हालांकि देखा गया नैदानिक परिणाम प्रासंगिक है और आगे की जांच को उचित ठहराता है।
अन्य अध्ययन रोगजनन संबंधी तर्क में योगदान करते हैं। Mohr और सहयोगियों ने गंभीर पार्वोवायरल एंटेराइटिस वाले कुत्तों में प्रदर्शित किया कि प्रारंभिक एंटेरल पोषण आंतों की पारगम्यता, आंतों के प्रोटीन हानि और नैदानिक परिणाम को प्रभावित करता है, जो रिकवरी में बाधा अखंडता के महत्व को मजबूत करता है। American Journal of Veterinary Research में प्रकाशित एक अध्ययन ने पुरानी एंटेरोपैथी वाले कुत्तों में जठरांत्र पारगम्यता और श्लेष्मा अवशोषण क्षमता का मूल्यांकन किया, पुष्टि करते हुए कि इस आबादी में बाधा शिथिलता मापनीय है। Ohno और सहयोगियों ने सचेत कुत्तों के प्रायोगिक मॉडल में देखा कि ग्लूटामाइन पेट की सर्जरी के बाद पोस्टऑपरेटिव आइलियस की अवधि कम करता है, जो गतिशीलता और कार्यात्मक आंतों की रिकवरी पर प्रभाव का सुझाव देता है।
कुल मिलाकर, ये अध्ययन प्रशंसनीयता और लाभ के संकेत का समर्थन करते हैं, लेकिन कैनाइन पुरानी एंटेरोपैथी में मानकीकृत प्रोटोकॉल तक एक्सट्रापोलेशन की अनुमति नहीं देते, ऐसा संदर्भ जिसमें ग्लूटामाइन का यादृच्छिक परीक्षणों में मूल्यांकन नहीं किया गया है।
5 बिल्लियों में साक्ष्य और FeLV+ संदर्भ
बिल्ली की स्थिति काफी भिन्न है। पुरानी एंटेरोपैथी, डिस्बायोसिस या किसी अन्य जठरांत्र स्थिति वाली बिल्लियों में ग्लूटामाइन पूरकता का मूल्यांकन करने वाले कोई यादृच्छिक नैदानिक परीक्षण नहीं मिले। प्रजाति पर लागू अधिकांश ज्ञान अन्य आबादी से एक्सट्रापोलेट किया गया है, जो स्पष्ट सीमाएं लगाता है।
उपलब्ध साक्ष्य अप्रत्यक्ष हैं। Kathrani और सहयोगियों ने Scientific Reports में प्रकाशित मेटाबोलोमिक अध्ययन में, हाइड्रोलाइज्ड प्रोटीन आहार प्राप्त करने वाली पुरानी एंटेरोपैथी वाली बिल्लियों का मूल्यांकन किया। ब्रिस्टल कोहोर्ट में, प्रवेश पर प्लाज्मा ग्लूटामाइन बीटाइन, ग्लिसरॉल और एलेनिन के साथ परिणाम के पूर्वानुमानक मेटाबोलाइट्स में से एक था। यह निष्कर्ष रॉयल वेटरनरी कॉलेज कोहोर्ट में दोहराया नहीं गया, और लेखक स्वयं विचलन को गंभीरता, रोग विषमता और छोटे नमूना आकार में अंतर के लिए जिम्मेदार ठहराते हैं। डेटा ग्लूटामाइन के मेटाबोलिक मार्कर के रूप में मूल्य का सुझाव देते हैं, स्थापित चिकित्सीय हस्तक्षेप के रूप में नहीं।
फेलाइन ल्यूकेमिया वायरस के संबंध में, यह एक ऑन्कोजेनिक रेट्रोवायरस है जो इम्यूनोसप्रेशन, एनीमिया और लिम्फोमा से जुड़ा है। Rolph और Cavanaugh, बिल्लियों में नियोप्लासिया के संक्रामक कारणों पर समीक्षा में, FeLV को प्रजाति में ऑन्कोजेनिक के रूप में मान्यता प्राप्त पहले एजेंटों में स्थापित करते हैं। वायरल इम्यूनोसप्रेशन आंतों की श्लेष्मा और GALT से समझौता करता है, डिस्बायोसिस, जीवाणु ट्रांसलोकेशन और अवसरवादी संक्रमणों को बढ़ावा देता है। Buchmann और सहयोगियों ने FeLV संक्रमण और बिल्लियों में Bartonella henselae के प्रति अधिक संवेदनशीलता के बीच महत्वपूर्ण संबंध प्रदर्शित किया, जो श्लेष्मा प्रतिरक्षा क्षमता पर वायरल इम्यूनोसप्रेशन के प्रभाव का साक्ष्य है।
इस परिदृश्य में, ग्लूटामाइन पूरकता के लिए विशेष रूप से सावधान जोखिम-लाभ विश्लेषण की आवश्यकता होती है। नियोप्लास्टिक कोशिकाओं में ग्लूटामाइन निर्भरता हो सकती है, जिसे ऑन्कोलॉजी साहित्य में ग्लूटामाइन एडिक्शन के रूप में वर्णित किया गया है। Muranaka और सहयोगियों, Cancers में प्रकाशित समीक्षा में, पूरकता, जो आंतों की अखंडता और प्रतिरक्षा कार्य का समर्थन करती है, और ट्यूमरजेनेसिस को बढ़ावा देने की सैद्धांतिक संभावना के बीच नाजुक संतुलन पर चर्चा करते हैं। Fan और सहयोगियों, ग्लूटामाइन चयापचय को चिकित्सीय लक्ष्य के रूप में समीक्षा में, प्रसारित ट्यूमर कोशिकाओं के लिए नाइट्रोजन और कार्बन स्रोत के रूप में इस अमीनो अम्ल की भूमिका का वर्णन करते हैं।
यह पहचानना आवश्यक है कि यह साक्ष्य मानव और प्रायोगिक मॉडलों से आता है। लिम्फोमा के उच्च जोखिम वाली FeLV-पॉजिटिव बिल्लियों में ग्लूटामाइन पूरकता की सुरक्षा स्थापित करने वाला कोई पशु चिकित्सा डेटा नहीं है। इसलिए, निर्णय व्यक्तिगत होना चाहिए, नैदानिक स्टेजिंग, नियोप्लासिया की उपस्थिति, पोषण स्थिति और अनुदैर्ध्य निगरानी को ध्यान में रखते हुए।
6 सुरक्षा, खुराक और पद्धतिगत सीमाएं
यादृच्छिक पशु चिकित्सा नैदानिक परीक्षण में प्रलेखित एकमात्र खुराक 500 मिलीग्राम/किग्रा/दिन है, जो कैनाइन पार्वोवायरस अध्ययन में प्रयुक्त हुई। कुत्तों में पुरानी एंटेरोपैथी के लिए, या बिल्लियों में किसी भी स्थिति के लिए खुराक का कोई मानकीकरण नहीं है। जैवउपलब्धता, प्रशासन मार्ग, विभाजन और उपचार अवधि जैसे पहलू पशु चिकित्सा में अपरिभाषित हैं।
मानव साक्ष्य उत्साह के लिए एक महत्वपूर्ण प्रतिबिंदु प्रदान करते हैं। Abbasi और सहयोगियों ने Amino Acids में प्रकाशित व्यवस्थित समीक्षा और मेटा-विश्लेषण में, 352 प्रतिभागियों वाले दस नैदानिक परीक्षणों का विश्लेषण किया और निष्कर्ष निकाला कि ग्लूटामाइन पूरकता ने समग्र रूप से आंतों की पारगम्यता को महत्वपूर्ण रूप से नहीं बदला। प्रभाव केवल 30 ग्राम/दिन से अधिक खुराक पर और दो सप्ताह से कम अवधि के लिए महत्वपूर्ण हुआ। यह परिणाम सार्वभौमिक लाभ की अपेक्षा को सापेक्ष बनाता है और सामान्य सिफारिशों के प्रति वैज्ञानिक संदेह की आवश्यकता को मजबूत करता है।
Cruzat और सहयोगियों ने ग्लूटामाइन चयापचय और प्रतिरक्षा कार्य पर व्यापक समीक्षा में, इस बात पर प्रकाश डाला कि, हालांकि पूरकता के प्रतिरक्षा प्रभाव स्थापित हैं, विभिन्न अपचयी स्थितियों में इन विवो परिणामों के बारे में प्रासंगिक प्रश्न बने हुए हैं। Holeček, अमीनो अम्ल पूरकों के प्रतिकूल प्रभावों की समीक्षा करते हुए, चेतावनी देते हैं कि बढ़ा हुआ ग्लूटामाइन सेवन जोखिम-मुक्त नहीं है, जिसका गुर्दा कार्य, अमोनिया उत्पादन और झिल्ली ट्रांसपोर्टरों के लिए अन्य अमीनो अम्लों के साथ प्रतिस्पर्धा पर संभावित प्रभाव हो सकता है।
व्यावहारिक दृष्टिकोण से, फॉर्मूलेशन भी सीमाएं लगाता है: घोल में ग्लूटामाइन की अस्थिरता, परिवर्तनशील स्वाद और लंबे समय तक पूरकता की लागत ऐसे कारक हैं जो मालिक के पालन और प्रोटोकॉल की व्यवहार्यता को प्रभावित करते हैं।
7 नैदानिक एकीकरण: ग्लूटामाइन कहां फिट होता है
ग्लूटामाइन को सहायक के रूप में समझा जाना चाहिए, कभी भी मजबूत साक्ष्य आधार वाले हस्तक्षेपों के विकल्प के रूप में नहीं। पुरानी एंटेरोपैथी और डिस्बायोसिस में चिकित्सीय पदानुक्रम चार स्तंभों पर केंद्रित रहता है: पर्याप्त चिकित्सीय आहार, उपयुक्त रूप से हाइड्रोलाइज्ड प्रोटीन या उन्मूलन आहार का उपयोग; पेशेवर मार्गदर्शन के साथ बायोटिक्स प्रबंधन, जिसमें प्रीबायोटिक्स, प्रोबायोटिक्स, पोस्टबायोटिक्स और चयनित मामलों में फेकल माइक्रोबायोटा ट्रांसप्लांटेशन शामिल हैं; सूजन नियंत्रण; और विशिष्ट एटियोलॉजिकल उपचार।
López Martí और सहयोगियों की Journal of Small Animal Practice में प्रकाशित व्यवस्थित समीक्षा और मेटा-विश्लेषण ने बिल्लियों में बायोटिक्स की प्रभावशीलता का मूल्यांकन किया और निष्कर्ष निकाला कि साक्ष्य की निश्चितता निम्न से बहुत निम्न है, कुछ प्रोबायोटिक परीक्षणों में मल स्थिरता के संबंध में अनुकूल परिणाम थे, लेकिन बिना भेदभाव सिफारिश के लिए मजबूत समर्थन के। Whittemore और सहयोगियों ने यादृच्छिक नियंत्रित परीक्षण में प्रदर्शित किया कि सिंबायोटिक प्रशासन क्लिंडामाइसिन से उपचारित बिल्लियों के मल माइक्रोबायोम और मेटाबोलोम को नियंत्रित करता है, शॉर्ट-चेन फैटी एसिड, पित्त अम्ल और पॉलियामाइन मार्गों में परिवर्तन के साथ। Wang और सहयोगियों ने देखा कि पोस्टबायोटिक पूरकता ने बिल्लियों में आंतों की बाधा की अखंडता में सुधार किया, डायमाइन ऑक्सीडेज और लिपोपॉलीसेकेराइड जैसे पारगम्यता मार्करों में कमी के साथ, साथ ही इम्युनोग्लोबुलिन G और विरोधी-सूजन साइटोकिन्स में वृद्धि।
एकीकृत पशु चिकित्सा के दृष्टिकोण से, ग्लूटामाइन अन्य सूचना प्रवणताओं में जुड़ता है जो होमियोस्टेसिस बहाल करने की दिशा में अभिसरित होती हैं। एंडोकैनाबिनॉइड सिस्टम फार्माकोलॉजी पुरानी सूजन नियंत्रण और इम्यूनोमॉड्यूलेशन के लिए संसाधन प्रदान करती है; पुनर्योजी नैदानिक पोषण, जिसमें पेप्टाइड्स का अध्ययन शामिल है, ऊतक मरम्मत प्रक्रियाओं का समर्थन करना चाहता है; और माइक्रोबायोटा मॉडुलन वह नींव है जिस पर अन्य हस्तक्षेप टिके हैं। कैनाबिनॉइड्स और ग्लूटामाइन के बीच संबंध जैविक तर्क प्रस्तुत करता है, लेकिन विशिष्ट अंतःक्रिया अध्ययनों की कमी है, जिसे निर्धारण में विचार किया जाना चाहिए।
8 अंतिम विचार
ग्लूटामाइन में ठोस जैविक प्रशंसनीयता और कुत्तों में आशाजनक नैदानिक साक्ष्य हैं, विशेष रूप से कैनाइन पार्वोवायरस के संदर्भ में, जहां एक यादृच्छिक परीक्षण ने दस्त की अवधि में कमी और बेहतर मल स्कोर प्रदर्शित किया। हालांकि, ये निष्कर्ष छोटे नमूने से आते हैं और पद्धतिगत सीमाएं प्रस्तुत करते हैं जो तत्काल सामान्यीकरण को रोकती हैं।
पुरानी डिस्बायोसिस में, साक्ष्य दोनों प्रजातियों में कमजोर बना हुआ है। बिल्लियों में, यह व्यावहारिक रूप से अनुपस्थित है, केवल मेटाबोलोमिक डेटा तक सीमित है जो ग्लूटामाइन को स्थापित चिकित्सा के बजाय मार्कर के रूप में स्थापित करता है। फेलाइन ल्यूकेमिया वायरस से संक्रमित रोगियों में, नियोप्लासिया का बढ़ा हुआ जोखिम व्यक्तिगत मूल्यांकन की मांग करता है, क्योंकि इस परिदृश्य में पूरकता की सुरक्षा स्थापित नहीं हुई है।
उपभोक्ता-उन्मुख सामग्री का सीधा स्थानांतरण, विशेष रूप से सोशल मीडिया पर प्रसारित, प्रजाति, खुराक या नैदानिक संदर्भ के भेद के बिना, अनुचित और संभावित रूप से हानिकारक है। साक्ष्य-आधारित पशु चिकित्सा अभ्यास के लिए उपलब्ध ज्ञान की सीमाओं को पहचानना और उन्हें मालिक को पारदर्शी रूप से संचारित करना आवश्यक है।
निष्कर्ष यह है कि ग्लूटामाइन को सहायक स्थिति में रहना चाहिए, उच्च जैविक मूल्य प्रोटीन में पर्याप्त आहार आधार और सावधान माइक्रोबायोटा प्रबंधन पर, हमेशा व्यक्तिगत मूल्यांकन के साथ। अच्छी तरह से डिज़ाइन किए गए पशु चिकित्सा नैदानिक परीक्षण, मानकीकृत खुराक, परिणाम और आबादी के साथ, छोटे पशु अभ्यास में इस अमीनो अम्ल की भूमिका को सटीक रूप से परिभाषित करने के लिए आवश्यक हैं।
Claudio Amichetti Junior — CRMV 75404 पशु पोषण में स्नातकोत्तर · औषध विज्ञान में स्नातकोत्तर · चिकित्सीय भांग में स्नातकोत्तर
संदर्भ
KIM, Min-Hyun; KIM, Hyeyoung. The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. International Journal of Molecular Sciences, v. 18, n. 5, p. 1051, 2017. DOI: 10.3390/ijms18051051.
RAO, RadhaKrishna; SAMAK, Geetha. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. Current Nutrition & Food Science, v. 8, n. 1, p. 47-54, 2012. DOI: 10.2174/1875044301205010047.
SALAVATI SCHMITZ, Silke. Evidence-based use of biotics in the management of gastrointestinal disorders in dogs and cats. Veterinary Record, 2024. DOI: 10.1002/vetr.4916.
ISIDORI, Marco; CORBEE, Ronald Jan; TRABALZA-MARINUCCI, Massimo. Nonpharmacological Treatment Strategies for the Management of Canine Chronic Inflammatory Enteropathy — A Narrative Review. Veterinary Sciences, v. 9, n. 2, p. 37, 2022. DOI: 10.3390/vetsci9020037.
DRUT, Amandine; MKAOUAR, Héla; KRIAA, Aïcha; MARIAULE, Vincent; AKERMI, Nizar; MÉRIC, Tristan; SÉNÉCAT, Odile; MAGUIN, Emmanuelle; HERNANDEZ, Juan L.; RHIMI, Moez. Gut microbiota in cats with inflammatory bowel disease and low-grade intestinal T-cell lymphoma. Frontiers in Microbiology, v. 15, p. 1346639, 2024. DOI: 10.3389/fmicb.2024.1346639.
MAKIELSKI, Kelly M.; CULLEN, Jonah N.; O'CONNOR, Annette M. Cormier; JERGENS, Albert E. Narrative review of therapies for chronic enteropathies in dogs and cats. Journal of Veterinary Internal Medicine, v. 33, n. 1, p. 11-22, 2019. DOI: 10.1111/jvim.15345.
MELO, Alice Madeira Campos; GHEDIN, Victória; ROMANO, Felipe Saab; DOS SANTOS, Natalia Ribeiro; PELLEGRI, Lara Alice Pagura; ICHIKAWA, Ricardo Shoiti; HUSSNI, Maria Fernanda; PAES, Antônio Carlos; GUIMARÃES-OKAMOTO, Priscylla Tatiana Chalfun; RAHAL, Sheila Canevese; MELCHERT, Alessandra. Oral glutamine supplementation in dogs infected with canine parvovirus type 2. Topics in Companion Animal Medicine, v. 70, p. 101040, 2026. DOI: 10.1016/j.tcam.2025.101040.
MOHR, Albert J.; LEISEWITZ, Andrew L.; JACOBSON, Linda S.; STEINER, Jörg M.; RUAUX, Craig G. Effect of Early Enteral Nutrition on Intestinal Permeability, Intestinal Protein Loss, and Outcome in Dogs with Severe Parvoviral Enteritis. Journal of Veterinary Internal Medicine, v. 17, n. 6, 2003. DOI: 10.1111/j.1939-1676.2003.tb02516.x.
Evaluation of gastrointestinal permeability and mucosal absorptive capacity in dogs with chronic enteropathy. American Journal of Veterinary Research, v. 67, n. 3, p. 479, 2006.
OHNO, Tetsuro; MOCHIKI, Erito; ANDO, Hiroyuki; FUKASAWA, Takaharu; TOYOMASU, Yoshitaka; OGATA, Kyoichi; AIHARA, Ryuusuke; ASAO, Takayuki; KUWANO, Hiroyuki. Glutamine Decreases the Duration of Postoperative Ileus After Abdominal Surgery: An Experimental Study of Conscious Dogs. Digestive Diseases and Sciences, 2008. DOI: 10.1007/s10620-008-0478-5.
KATHRANI, Aarti; YEN, Sandi; HALL, Edward J.; SWANN, Jonathan Richard. The effects of a hydrolyzed protein diet on the plasma, fecal and urine metabolome in cats with chronic enteropathy. Scientific Reports, v. 13, p. 19979, 2023. DOI: 10.1038/s41598-023-47334-y.
ROLPH, Kerry E.; CAVANAUGH, Ryan Patrick. Infectious Causes of Neoplasia in the Domestic Cat. Veterinary Sciences, v. 9, n. 9, p. 467, 2022. DOI: 10.3390/vetsci9090467.
BUCHMANN, Alexandra U.; KERSHAW, Olivia; KEMPF, Volkhard A. J.; GRUBER, Achim D. Does a Feline Leukemia Virus Infection Pave the Way for Bartonella henselae Infection in Cats? Journal of Clinical Microbiology, v. 48, n. 9, 2010. DOI: 10.1128/JCM.00750-10.
MURANAKA, Hayato; AKINSOLA, Rasaq; BILLET, Sandrine; PANDOL, Stephen Jacob; HENDIFAR, Andrew Eugene; BHOWMICK, Neil A.; GONG, Jun. Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention. Cancers, v. 16, n. 5, p. 1057, 2024. DOI: 10.3390/cancers16051057.
FAN, Yuxin; HAN, Xue; LI, Zhimin; HUO, Mingge; GAO, Hongxia; GUAN, Xingang. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment. Frontiers in Pharmacology, v. 15, p. 1345522, 2024. DOI: 10.3389/fphar.2024.1345522.
ABBASI, Fatemeh; HAGHIGHAT LARI, Mohammad Mehdi; KHOSRAVI, Gholamreza Reza; MANSOURI, Elahe; PAYANDEH, Nastaran; MILAJERDI, Alireza. A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults. Amino Acids, 2024. DOI: 10.1007/s00726-024-03420-7.
CRUZAT, Vínicius Fernandes; ROGERO, Marcelo Macedo; KEANE, Kevin Noel; CURI, Rui; NEWSHOLME, Philip. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, v. 10, n. 11, p. 1564, 2018. DOI: 10.3390/nu10111564.
HOLEČEK, Milan. Side Effects of Amino Acid Supplements. Physiological Research, v. 71, n. 1, p. 29-45, 2022. DOI: 10.33549/physiolres.934790.
LÓPEZ MARTÍ, Á.; MONTERO PALMA, C.; LÓPEZ MARTÍ, H.; RANCHAL SÁNCHEZ, A. Efficacy of probiotic, prebiotic, synbiotic and postbiotic supplementation on gastrointestinal health in cats: systematic review and meta-analysis. Journal of Small Animal Practice, v. 66, n. 4, p. 219-232, 2025. DOI: 10.1111/jsap.13822.
WHITTEMORE, Jacqueline C.; STOKES, Jennifer E.; PRICE, Joshua M.; SUCHODOLSKI, Jan S. Effects of a synbiotic on the fecal microbiome and metabolomic profiles of healthy research cats administered clindamycin: a randomized, controlled trial. Gut Microbes, v. 10, n. 4, p. 521-539, 2019. DOI: 10.1080/19490976.2018.1560754.
WANG, Weiwei; MIAO, Chengyi; CHEN, Qianqian; WANG, Longjiao; CHANG, Xiaohan; ZHAO, Lili; MA, Wenqiang; LEI, Shanyu; MA, Mengyao; ZHANG, Yuqiang; CHEN, Shuxing; CHEN, Lishui; WANG, Ran; GE, Shaoyang; XIONG, Wei. Postbiotic supplementation promotes gut barrier integrity and immune balance in cats via microbiota modulation. Frontiers in Microbiology, v. 16, p. 1692845, 2025. DOI: 10.3389/fmicb.2025.1692845.
YANG, Benlu; ZHONG, Shengwei; WANG, Jue; YU, Wanting. Dietary Modulation of the Gut Microbiota in Dogs and Cats and Its Role in Disease Management. Microorganisms, v. 13, n. 12, p. 2669, 2025. DOI: 10.3390/microorganisms13122669.
